var title_f35_60_36800="Dorsoinferior transver lie2";
var content_f35_60_36800=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dorsoinferior transverse lie",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 412px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anatomical Chart Company. Copyright 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_60_36800=[""].join("\n");
var outline_f35_60_36800=null;
var title_f35_60_36801="Chondroblastoma humerus";
var content_f35_60_36801=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chondroblastoma of the humerus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 480px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Greater tuberosity of the humerus. Observe the oval, geographic lesion within the greater tuberosity apophysis (arrows). This is a characteristic location for chondroblastoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_60_36801=[""].join("\n");
var outline_f35_60_36801=null;
var title_f35_60_36802="Physical examination maneuver for osteitis pubis";
var content_f35_60_36802=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Physical examination maneuver for osteitis pubis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 451px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To assess the adductor and lower abdominal muscles, the patient should be placed supine on the examining table with hips and knees flexed 90 degrees. The athlete then performs an isometric adductor muscle contraction against the examiner's fist. A painful isometric muscle contraction is considered a positive test",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_60_36802=[""].join("\n");
var outline_f35_60_36802=null;
var title_f35_60_36803="Flumazenil: Patient drug information";
var content_f35_60_36803=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Flumazenil: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/6/41062?source=see_link\">",
"     see \"Flumazenil: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/58/38821?source=see_link\">",
"     see \"Flumazenil: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F172027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Romazicon&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F172028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Anexate&reg;;",
"     </li>",
"     <li>",
"      Flumazenil Injection;",
"     </li>",
"     <li>",
"      Flumazenil Injection, USP;",
"     </li>",
"     <li>",
"      Romazicon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10016360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700749",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause seizures in some patients. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692136",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to wake you up after surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692068",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat side effects after benzodiazepine (eg, alprazolam, diazepam, and lorazepam) overdose.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to flumazenil or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697801",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may not be alert. Avoid driving and doing other tasks or actions until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697908",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain and irritation where this drug goes into the body.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12497 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-82D89F4E57-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_60_36803=[""].join("\n");
var outline_f35_60_36803=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172027\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172028\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016360\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016362\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016361\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016366\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016367\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016369\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016364\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016371\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/6/41062?source=related_link\">",
"      Flumazenil: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/58/38821?source=related_link\">",
"      Flumazenil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_60_36804="Low-renin essential (primary) hypertension";
var content_f35_60_36804=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Low-renin essential (primary) hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/60/36804/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/60/36804/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/60/36804/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/60/36804/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/60/36804/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/60/36804/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/60/36804/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renin-sodium profiling in patients with essential (primary) hypertension reveals that the plasma renin activity (PRA) is increased in 15 percent, normal in 60 percent, and reduced in approximately 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/1\">",
"     1",
"    </a>",
"    ]. Low renin levels are found more frequently in blacks and in the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although it is likely that patients with low-renin essential hypertension (LREH) represent part of a continuum of hypertensives, this subgroup may have some relatively unique characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The elevation in blood pressure is more likely to be salt-sensitive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The response to nonpharmacologic therapy, particularly weight reduction, may be less pronounced [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The antihypertensive response may be greatest with a diuretic or calcium channel blocker [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/1,3,5\">",
"       1,3,5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review issues related to low renin essential hypertension. The general evaluation of patients with hypertension is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/422?source=see_link\">",
"     \"Initial evaluation of the hypertensive adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A higher perfusion pressure at the juxtaglomerular cell that may be seen in essential hypertension would be expected to lead to suppression of renin release and low levels of PRA. This is supported by the observation that some patients with essential hypertension tend to have lower PRA levels than age- and gender-matched normotensive individuals. However, the majority of patients with primary hypertension do not have low renin levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to LREH, there are a variety of other causes of hypertension associated with low PRA. These include primary aldosteronism and a variety of less common disorders including apparent mineralocorticoid excess (either genetic or acquired with licorice ingestion), congenital adrenal hyperplasia, glucocorticoid-remediable hyperaldosteronism, and Liddle syndrome (leading to increased collecting tubule sodium channel activity independent of mineralocorticoids) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=see_link&amp;anchor=H11#H11\">",
"     \"Approach to the patient with hypertension and hypokalemia\", section on 'Nonaldosterone mineralocorticoid excess'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28391?source=see_link\">",
"     \"Adrenal steroid biosynthesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22615?source=see_link\">",
"     \"Familial hyperaldosteronism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9159?source=see_link\">",
"     \"Genetic factors in the pathogenesis of essential hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mineralocorticoid excess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppressed renin release is one of the hallmarks of hypertension, induced by excess mineralocorticoid activity (as with primary hyperaldosteronism) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/6\">",
"     6",
"    </a>",
"    ]. The role of mineralocorticoid excess in LREH is supported by the observation that such patients derive greater blood pressure reduction with mineralocorticoid antagonism than with other antihypertensive drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with LREH typically lack the hypokalemia that is considered characteristic of primary hyperaldosteronism. However, it has become clear that primary aldosteronism often causes low PRA and hypertension in the absence of hypokalemia. Among patients with primary aldosteronism who are detected by screening using the plasma aldosterone-to-plasma renin ratio, as many as 60 percent are normokalemic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/8\">",
"     8",
"    </a>",
"    ]. Normokalemia is also common (about 50 percent) in patients with the genetic disorder glucocorticoid-remediable aldosteronism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22615?source=see_link\">",
"     \"Familial hyperaldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subtle defects in cortisol physiology have been associated with LREH, including increased levels of 18-hydroxylated steroids, and activation of the mineralocorticoid receptor by cortisol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40838?source=see_link\">",
"     \"Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9159?source=see_link\">",
"     \"Genetic factors in the pathogenesis of essential hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Increased tissue angiotensin II activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reduced plasma renin activity in LREH does not exclude local angiotensin II activity in the tissues (such as vascular endothelium, the kidneys, the brain, and the adrenal glands) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/10\">",
"     10",
"    </a>",
"    ]. In the kidney, for example, the local concentration of angiotensin II in the glomerular filtrate and peritubular capillary (which are adjacent to the juxtaglomerular apparatus from which renin is released) is 1000 times higher than that circulating in the plasma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/11\">",
"     11",
"    </a>",
"    ]. It is therefore possible to have activation of the renin-angiotensin system within the kidney that is not detectable from measurement of the plasma renin activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possible importance of tissue renin-angiotensin systems is suggested by the blood pressure lowering effect of angiotensin converting enzyme (ACE) inhibitors even in patients with low plasma renin levels. Such a role was demonstrated in transgenic rats into which a mouse renin gene was inserted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/13\">",
"     13",
"    </a>",
"    ]. Despite evidence for angiotensin-mediated hypertension, the plasma renin activity, plasma angiotensin II level, and renal renin content were all below normal, while adrenal renin content, vascular angiotensin II formation, and the plasma level of prorenin (the precursor of active renin) were markedly elevated. Possible examples of the involvement of tissue renin-angiotensin systems in the genesis of hypertension in humans are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25224?source=see_link\">",
"     \"Renin-angiotensin system inhibition in the treatment of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with LREH may have a lower risk of cardiovascular disease than hypertensive patients with normal or high renin levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], although this has not been consistently noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36825?source=see_link&amp;anchor=H8#H8\">",
"     \"Actions of angiotensin II on the heart\", section on 'Direct cardiac effects of angiotensin II'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a plausible rationale for the efficacy of a variety of antihypertensive drugs in LREH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Given the possible role of salt- and volume-sensitivity in patients with LREH, it has been proposed that such patients would respond best to diuretics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/1,4\">",
"       1,4",
"      </a>",
"      ]. However, increased sensitivity to diuretics has not been found in all studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Since mineralocorticoid excess can play a role in LREH, mineralocorticoid receptors antagonists such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      are often effective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is an adequate long-term antihypertensive response to ACE inhibitors and angiotensin II receptor blockers (ARBs) that is unrelated to baseline levels of PRA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]. However, the response to angiotensin inhibition may be less than that with a mineralocorticoid receptor antagonist [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although it has been proposed that therapeutic choices of antihypertensive drugs should be based upon the PRA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/22\">",
"     22",
"    </a>",
"    ], patients with LREH do not predictably respond better to particular antihypertensive agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36804/abstract/11\">",
"     11",
"    </a>",
"    ]. Furthermore, measurement of PRA is not part of standard management of patients with essential hypertension. Thus, these patients are treated similarly to other patients with essential hypertension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with essential hypertension, the PRA is decreased in approximately 25 percent, normal in 60 percent, and increased in 15 percent. Patients with LREH may have a lower risk of cardiovascular disease than hypertensive patients with normal or high renin levels (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Prognosis'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    There is no evidence that PRA profiling is useful for determining the response to particular antihypertensive agents in patients with essential hypertension. As a result, we recommend not routinely measuring PRA in the assessment and management of patients with essential hypertension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to the patient with hypertension and hypokalemia\", section on 'Is there a role for routine screening?'",
"    </a>",
"    .) Patients with low renin hypertension do not predictably respond better to particular antihypertensive agents. Thus, we recommend following general guidelines for the treatment of hypertension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/1\">",
"      B&uuml;hler FR, Bolli P, Kiowski W, et al. Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients. Am J Med 1984; 77:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/2\">",
"      Sagnella GA. Why is plasma renin activity lower in populations of African origin? J Hum Hypertens 2001; 15:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/3\">",
"      Laragh JH, Resnick LM. Recognizing and treating two types of long-term vasoconstriction in hypertension. Kidney Int Suppl 1988; 25:S162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/4\">",
"      Blaufox MD, Lee HB, Davis B, et al. Renin predicts diastolic blood pressure response to nonpharmacologic and pharmacologic therapy. JAMA 1992; 267:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/5\">",
"      B&uuml;hler FR. Calcium antagonists as first-choice therapy for low-renin essential hypertension. Kidney Int 1989; 36:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/6\">",
"      Mackenzie IS, Brown MJ. Molecular and clinical investigations in patients with low-renin hypertension. Clin Exp Nephrol 2009; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/7\">",
"      Hood SJ, Taylor KP, Ashby MJ, Brown MJ. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation 2007; 116:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/8\">",
"      Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/9\">",
"      Rossi E, Regolisti G, Perazzoli F, et al. -344C/T polymorphism of CYP11B2 gene in Italian patients with idiopathic low renin hypertension. Am J Hypertens 2001; 14:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/10\">",
"      Johnston CI. Franz Volhard Lecture. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens Suppl 1992; 10:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/11\">",
"      Seikaly MG, Arant BS Jr, Seney FD Jr. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest 1990; 86:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/12\">",
"      Redgrave J, Rabinowe S, Hollenberg NK, Williams GH. Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertensives. J Clin Invest 1985; 75:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/13\">",
"      Bachmann S, Peters J, Engler E, et al. Transgenic rats carrying the mouse renin gene--morphological characterization of a low-renin hypertension model. Kidney Int 1992; 41:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/14\">",
"      B&uuml;hler FR, Laragh JH, Baer L, et al. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 1972; 287:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/15\">",
"      Alderman MH, Madhavan S, Ooi WL, et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/16\">",
"      Meade TW, Cooper JA, Peart WS. Plasma renin activity and ischemic heart disease. N Engl J Med 1993; 329:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/17\">",
"      Wyndham RN, Gimenez L, Walker WG, et al. Influence of renin levels on the treatment of essential hypertension with thiazide diuretics. Arch Intern Med 1987; 147:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/18\">",
"      Weinberger MH, White WB, Ruilope LM, et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 2005; 150:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/19\">",
"      Sassano P, Chatellier G, Billaud E, et al. Treatment of mild to moderate hypertension with or without the converting enzyme inhibitor enalapril. Results of a six-month double-blind trial. Am J Med 1987; 83:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/20\">",
"      Azizi M, Bissery A, Bura-Rivi&egrave;re A, M&eacute;nard J. Dual renin-angiotensin system blockade restores blood pressure-renin dependency in individuals with low renin concentrations. J Hypertens 2003; 21:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/21\">",
"      Weir MR, Saunders E. Renin status does not predict the anti-hypertensive response to angiotensin-converting enzyme inhibition in African-Americans. Trandolapril Multicenter Study Group. J Hum Hypertens 1998; 12:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36804/abstract/22\">",
"      Laragh JH, Sealey JE. Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT. Am J Hypertens 2003; 16:407.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3839 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-89.32.226.102-21F53BA666-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_60_36804=[""].join("\n");
var outline_f35_60_36804=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mineralocorticoid excess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Increased tissue angiotensin II activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36825?source=related_link\">",
"      Actions of angiotensin II on the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28391?source=related_link\">",
"      Adrenal steroid biosynthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40838?source=related_link\">",
"      Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=related_link\">",
"      Approach to the patient with hypertension and hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22615?source=related_link\">",
"      Familial hyperaldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9159?source=related_link\">",
"      Genetic factors in the pathogenesis of essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/422?source=related_link\">",
"      Initial evaluation of the hypertensive adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25224?source=related_link\">",
"      Renin-angiotensin system inhibition in the treatment of hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_60_36805="Perirenal fascia sagittal view";
var content_f35_60_36805=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F85917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F85917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Perirenal fascia sagittal view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 534px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal view depicting the perirenal fascia. The anterior fascia was called Gerota's fascia while the posterior fascia was called Zuckerkandl's fascia. The perirenal fascia envelops each kidney and adrenal gland together with a surrounding layer of adipose tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_60_36805=[""].join("\n");
var outline_f35_60_36805=null;
var title_f35_60_36806="Behavioral sleep problems in children";
var content_f35_60_36806=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Behavioral sleep problems in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/60/36806/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/60/36806/contributors\">",
"     Judith A Owens, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/60/36806/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/60/36806/contributors\">",
"     Ronald D Chervin, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/60/36806/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/60/36806/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/60/36806/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral sleep problems (behavioral insomnia) in children include bedtime refusal or resistance, delayed sleep onset, and prolonged night awakenings requiring parental intervention. All of these issues are common in the pediatric population, and often adversely affect the quality of life of both children and caregivers.",
"   </p>",
"   <p>",
"    Medical issues, including medications, pain, and primary sleep disorders (eg, obstructive sleep apnea), may also cause sleep problems either directly or by contributing to behavioral sleep problems by triggering poor sleep hygiene or negative sleep onset associations.",
"   </p>",
"   <p>",
"    The causes and interventions appropriate to behavioral sleep problems, which are the most common sleep issues in children, will be reviewed here. The general clinical evaluation of sleep problems in children, including the steps needed to determine whether the problem is behavioral in origin, is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5929?source=see_link\">",
"     \"Assessment of sleep disorders in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three main categories of insomnia in children: behavioral insomnia of childhood, primary (psychophysiologic) insomnia, and transient forms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Behavioral insomnia of childhood",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2005 revision of the International Classification of Sleep Disorders (ICSD) introduced a new clinical diagnostic category of behavioral insomnia of childhood that includes sleep onset association and limit setting subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36806/abstract/1\">",
"     1",
"    </a>",
"    ]. Although these two issues are separated for diagnostic purposes, they often coexist, and many children present with both bedtime delays and night awakenings.",
"   </p>",
"   <p>",
"    The diagnostic criteria for a sleep disorder require that a specific constellation of symptoms meet a defined severity level, persist for a specified time, and result in significant impairment of functioning in the child, parent(s), or family. Behavioral insomnia of childhood is most common in young children aged zero to five years, but may persist into middle childhood and beyond.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Sleep onset association subtype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presenting problem in this subtype of behavioral insomnia is generally one of prolonged night waking that results in insufficient sleep. In this disorder, the infant or child has learned to fall asleep only under certain conditions or has specific sleep associations that require parental intervention, such as being rocked or fed, which are usually readily available at bedtime. During the night, when the child experiences the type of brief arousal that normally occurs at the end of each 60- to 90-minute sleep cycle, or awakens for other reasons, he is not able to get back to sleep (\"self-soothe\") unless those same conditions are available to him. The infant then \"signals\" the caregiver by crying or coming into the parents' bedroom if the child is no longer in a crib until the necessary associations are provided.",
"   </p>",
"   <p>",
"    This problem can be avoided or attenuated by the practice of putting the infant or child to bed while drowsy but still awake. This practice avoids creation of an association between sleep onset and being held or rocked.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Limit-setting subtype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limit-setting subtype of behavioral insomnia is most common in children preschool-aged and older. It is characterized by active resistance, verbal protests, and repeated demands at bedtime (\"curtain calls\") rather than night wakings. If sufficiently prolonged, the sleep onset delay may result in inadequate sleep. Some children present with nighttime fears characterized by fearful behaviors (eg, crying, clinging, or leaving the bedroom to seek parental reassurance), but these are a manifestation of bedtime stalling rather than anxiety.",
"   </p>",
"   <p>",
"    This disorder most commonly develops from a caregiver's inability or unwillingness to set consistent bedtime rules and enforce a regular bedtime. The problem is often exacerbated by the child's oppositional behavior. In some cases, however, the child's resistance at bedtime reflects an underlying problem in falling asleep caused by other factors, such as asthma, medication use, or other medical conditions; a sleep disorder, such as restless legs syndrome or anxiety; or a mismatch between the child's intrinsic circadian preferences (\"night owl\") and parental expectations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Primary (psychophysiologic) insomnia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The form of sleep onset or sleep maintenance insomnia defined in adults as primary (psychophysiologic) insomnia may also occur in the pediatric population, primarily in older children and adolescents. In this disorder, the individual develops conditioned anxiety around difficulty falling or staying asleep. Heightened physiologic and emotional arousal ensue, and further compromise the ability to sleep. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9561?source=see_link&amp;anchor=H10#H10\">",
"     \"Types of insomnia\", section on 'Psychophysiological insomnia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This type of insomnia frequently arises from a combination of predisposing factors that may include genetic vulnerability, medical disorders, or psychiatric conditions; precipitating factors, such as acute stress; and perpetuating factors, such as poor sleep habits, caffeine use, or maladaptive cognitions about sleep.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Transient forms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient sleep disturbances can occur in a child with previously normal sleep. A self-limited period of night wakings, such as that seen in \"adjustment insomnia\", can be the result of a stressful life event. Disruption of sleep schedule on a trip can cause jet lag. Many illnesses also can disturb sleep. Such short-term sleep disturbances, however, can become chronic if parents respond in a way that reinforces the night wakings and fosters inappropriate sleep habits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twenty to 30 percent of children in cross-sectional studies have significant bedtime problems",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    night waking, and in most cases, these have behavioral causes and solutions. The estimated prevalence of behavioral sleep disturbances in children is remarkably similar across studies, despite some variation in the definitions used.",
"   </p>",
"   <p>",
"    Behavioral sleep problems are found in all age groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants and toddlers &mdash; Night wakings are one of the most common sleep problems in infants and toddlers; 25 to 50 percent of children over the age of six months continue to awaken during the night [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36806/abstract/2\">",
"       2",
"      </a>",
"      ]. Bedtime resistance is found in 10 to 15 percent of toddlers.",
"     </li>",
"     <li>",
"      Preschool-aged children &mdash; Fifteen to 30 percent of preschool-aged children have difficulties falling asleep or night wakings, and in many cases, these issues coexist in the same child [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36806/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Middle childhood &mdash; Although previously thought to be rare in middle childhood, more recent surveys suggest that sleep problems are present in 25 to 40 percent of 4- to 10-year old children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36806/abstract/4\">",
"       4",
"      </a>",
"      ]. Fifteen percent of these children have bedtime resistance, and almost 11 percent have sleep-related anxiety.",
"     </li>",
"     <li>",
"      Adolescents &mdash; Studies have estimated that 11 percent of adolescents (13 to 16 years of age) have a history of significant insomnia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36806/abstract/5\">",
"       5",
"      </a>",
"      ]. Children with neurodevelopmental (ie, autism, mental retardation) and psychiatric disorders (ie, depression, anxiety, attention deficit hyperactivity disorder) are at particularly high risk for sleep disturbances.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Childhood insomnia involves intrinsic factors (those that are inborn or unique to the child and predispose to sleep problems), and extrinsic factors (environmental stimuli or caregivers' response) that precipitate or perpetuate the problem. A study in a cohort of twins (average age 16 months) estimated that approximately 66 percent of the variance in sleep duration was attributable to shared environmental effects, and about 26 percent to genetic effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36806/abstract/6\">",
"     6",
"    </a>",
"    ]. Shared environmental factors were responsible for about 55 percent of sleep disturbance, which was defined as a parent report that the child regularly wakes up on one or more nights per week. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Intrinsic factors that predispose or contribute to sleep problems include the child's temperament, medical issues, circadian preferences (\"night owl\" versus \"morning lark\"), neurodevelopmental disabilities, or anxiety disorders.",
"   </p>",
"   <p>",
"    Extrinsic factors include characteristics of the parents or caregiver that interfere with their ability to set clear limits both during the day and at bedtime. These factors can include mental illness, emotional stress, distraction by other responsibilities, or long work hours. In other cases, a \"mismatch\" arises between parental expectations for sleep behaviors and the normal developmental trajectory. Finally, environmental factors may contribute to poor limit-setting or negative sleep-onset associations. Examples include living accommodations that require a child to share a bedroom with a sibling, parent, or additional family members (eg, grandparents) residing in the home.",
"   </p>",
"   <p>",
"    In many cases, a sleep problem represents a combination of intrinsic and extrinsic factors. For example, \"fussy\" children may insist on a particular type of",
"    <span class=\"nowrap\">",
"     soothing/sleep-inducing",
"    </span>",
"    technique, resisting any alternative that is less dependent on the caregiver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36806/abstract/7\">",
"     7",
"    </a>",
"    ]. When responding to the behavior, inexperienced parents may inadvertently increase the undesired behavior (ie, crying or getting out of bed) by providing attention and reinforcement, instead of ignoring the behavior and, thereby, reducing its likelihood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of problematic sleep in children is often more complex than in adults for a number of reasons. First, the patient is rarely the one who presents with a chief complaint of sleeplessness. Thus, parental concerns and subjective observations regarding their child's sleep patterns and behaviors often define sleep disturbances in the clinical context. Second, sleep problems in the pediatric population must be viewed against a background of the normal developmental trajectory across childhood and developmental norms. \"Normal\" bedtime behavior, time to sleep onset, and sleep duration are dramatically different in children of different ages. Finally, cultural differences in sleep practices (eg, sleeping space and environment, solitary sleep versus cosleeping) have a profound effect on how a parent defines a sleep \"problem\", and also on the relative acceptability of various treatment strategies.",
"   </p>",
"   <p>",
"    The general clinical evaluation of sleep problems in children, including the steps needed to determine whether the problem is behavioral in origin, is discussed in detail in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5929?source=see_link\">",
"     \"Assessment of sleep disorders in children\"",
"    </a>",
"    .) For behavioral sleep problems, the following elements are particularly important to understand the origin of the problem and plan treatment strategies:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the medical history in children with insomnia is generally benign, the presence of medical issues may predispose a child to night wakings and may also increase the likelihood that parents will intervene during the night. Medical conditions that may predispose to sleep problems include allergies and atopic dermatitis, migraine headaches, seizure disorders, other rheumatologic conditions (eg, chronic fatigue syndrome and fibromyalgia), and chronic gastrointestinal disorders (eg, inflammatory bowel disease). Comorbid medical problems may also make behavioral strategies that involve \"extinction\" procedures (see below) more challenging for parents to implement successfully.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Developmental history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmentally delayed children often have sleep problems that reflect the child's developmental (younger) age rather than chronological age, and frequently have more severe and intractable sleep problems. The presence of a mental health disorder on psychiatric history and the use of psychotropic medications are also risk factors for insomnia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family history for insomnia or psychopathology, and especially maternal depression, can sometimes clarify a child's sleep problem or its roots.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Behavioral assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral assessment may identify the presence of risk factors for insomnia, such as difficult temperament. It may also identify behavioral consequences of the insomnia, such as irritability, inattentiveness, hyperactivity and impulsivity or increased aggression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep diaries or logs may be extremely helpful in further delineating the timing and nature of bedtime resistance or night wakings.",
"   </p>",
"   <p>",
"    The physical examination is usually noncontributory, and diagnostic tests, including overnight polysomnography, are not typically indicated unless symptoms suggest an underlying medical or sleep disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     BEHAVIORAL INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral interventions are the mainstay of treatment for behavioral insomnia of childhood. A review of 52 treatment studies indicates that behavioral therapies produce reliable and durable changes for both bedtime resistance and night wakings in young children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36806/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Ninety-four percent of the studies reported that behavioral interventions were effective. More than 80 percent of treated children demonstrated clinically significant improvement that was maintained at short (&lt;6 months), intermediate (6 to 12 months), and long range follow-up (&gt;12 months). No study reported detrimental effects. A number of studies also found positive effects of sleep interventions on secondary child-related outcome variables, including daytime behavior (eg, crying, irritability, detachment, self esteem, or emotional well-being). Sleep related behavioral intervention also led to improvement in the well-being of the parents with effects on mood, stress, or marital satisfaction in a number of studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36806/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the interventions described in these studies could be placed into the following categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bedtime routines",
"     </li>",
"     <li>",
"      Systematic ignoring (or \"extinction\") and its variants",
"     </li>",
"     <li>",
"      Bedtime fading",
"     </li>",
"     <li>",
"      Positive reinforcement",
"     </li>",
"     <li>",
"      Parent",
"      <span class=\"nowrap\">",
"       education/prevention",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Bedtime routines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishment of a consistent bedtime routine significantly improves both bedtime difficulties and night wakings. The routine should last about 20 to 45 minutes and include three to four soothing activities, such as taking a bath, changing into pajamas, and reading stories; it should not include television [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36806/abstract/11\">",
"     11",
"    </a>",
"    ]. The introduction at bedtime of more appropriate sleep associations should be readily available to the child during the night, and can include transitional objects such as a blanket or toy. The child should be put to bed drowsy but awake, to minimize dependence upon parental presence at sleep onset.",
"   </p>",
"   <p>",
"    An integral part of the bedtime routine is the institution of a bedtime and sleep schedule that ensures a developmentally appropriate amount of sleep. The bedtime should coincide with the child's natural sleep onset time. A consistent nightly bedtime will help to reinforce the circadian clock and enable the child to fall asleep more easily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Systematic ignoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic ignoring typically involves a program of withdrawal of parental assistance at sleep onset and during the night. When consistently applied, systematic ignoring usually achieves \"extinction\" of the need for parental assistance.",
"   </p>",
"   <p>",
"    Unmodified extinction (\"crying it out\") involves putting the child to bed at a designated bedtime and then ignoring the child until a set time the next morning. Although this approach has been documented to be a highly successful treatment, it is often not acceptable to families; parents are often unable to tolerate the child's crying and protest behavior and are less likely to be compliant.",
"   </p>",
"   <p>",
"    Graduated extinction is an alternative approach that weans the child from dependence upon parental presence; it involves putting the child to bed drowsy but awake, and waiting progressively longer periods of time before checking on the child. On each subsequent night, the initial waiting period before checking is increased by a specified number of minutes. When parents check on their child, they should reassure the child but keep contact brief (one to two minutes) and neutral (eg, pat on shoulder rather than pick up and cuddle). Since the goal of this treatment is to allow the child to fall asleep independently, there is no recommended \"optimal\" period of time between checks, and the amount of time should be determined by the parents' tolerance for crying and the child's temperament. As an example, a child who becomes more agitated with brief parental checks may do better with infrequent checks.",
"   </p>",
"   <p>",
"    Graduated extinction is effective even if instituted only at bedtime. Within one to two weeks after the child has learned to fall asleep easily and quickly at bedtime, the self-soothing skills usually generalize to nighttime arousals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to develop a strategy that gradually eliminates adult intervention, the clinician and parents should collaborate to develop a specific plan. They should identify an end goal, such as falling asleep independently at bedtime, and outline successive steps to achieve that goal. For example, a plan might include three days of establishing a bedtime routine and target bedtime, three nights of the parent sitting with the child at the bedside until she falls asleep, three nights of sitting in the child's bedroom doorway, followed by three nights of sitting outside doorway.",
"   </p>",
"   <p>",
"    More gradual fading of adult intervention may be more appropriate for families that either are unable to tolerate the above extinction approaches or consider them to be unacceptable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Bedtime fading",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bedtime fading involves temporarily setting bedtime to the current sleep onset time and then gradually advancing the time of lights out. This strategy is particularly helpful in children who have an \"evening\" circadian preference. The initial bedtime is set to coincide with the natural sleep onset time when the child is more physiologically ready for sleep, and the circadian preference is then gradually modified by setting the bedtime earlier over a period of several weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Positive reinforcement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reinforcement strategies, such as sticker charts, can be beneficial with preschoolers and older children. Such systems are most effective if rewards can be earned immediately. For example, the sticker reward should be given first thing in the morning if the child has met the goal. In addition, the goals must be obtainable, to reinforce success. For example, a child may initially earn a sticker just for sleeping in his own bed all night, even in the face of frequent calls to parents. With time, more challenging goals can be implemented.",
"   </p>",
"   <p>",
"    For school-aged children, the rewards can be modified as appropriate to the child's interests, but they should still be concrete and immediate. Multiple small rewards are generally more effective than fewer larger rewards.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Parent education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Problems with limit setting generally respond to some combination of the following behavioral strategies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreased parental attention for bedtime-delaying behavior",
"     </li>",
"     <li>",
"      Establishment of a consistent bedtime routine that does not include stimulating activities (eg, television viewing)",
"     </li>",
"     <li>",
"      Bedtime fading",
"     </li>",
"     <li>",
"      Positive reinforcement for appropriate behavior at bedtime",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For all of these behavioral strategies, it is critical that education be provided to parents about normal sleep development at different ages, good sleep hygiene, and basic behavioral principles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36806/abstract/12\">",
"     12",
"    </a>",
"    ]. As an example, parents must understand the need for consistency in applying behavioral programs to avoid inadvertent intermittent reinforcement of the undesired behaviors. Parents should also be forewarned that protest behavior frequently escalates temporarily at the beginning of treatment (this is known as a \"post-extinction burst\").",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OLDER CHILDREN AND ADOLESCENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of primary insomnia in older children and adolescents usually involves similar behavioral interventions as are used in adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13290?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of insomnia\", section on 'Behavioral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Established strategies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Education of the child or adolescent about principles of sleep hygiene (in particular, keeping a regular sleep schedule and not \"sleeping in\" on weekends) (",
"      <a class=\"graphic graphic_table graphicRef52760 \" href=\"mobipreview.htm?39/24/40331\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Instruction of the child or adolescent to use the bed for sleep only and to get out of bed if unable to fall asleep (stimulus control)",
"     </li>",
"     <li>",
"      Restriction of time in bed to the actual time asleep (sleep restriction)",
"     </li>",
"     <li>",
"      Use of relaxation techniques and cognitive-behavioral strategies to reduce anxiety",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the vast majority of sleep disturbances in children are successfully managed with behavior therapy alone, a combination of behavioral and pharmacological intervention may be appropriate in selected clinical situations and in specific populations, such as children with ADHD or autism spectrum disorders. If medication is thought to be potentially beneficial in a given clinical situation, the following guidelines should be kept in mind [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36806/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With the exception of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/38/2662?source=see_link\">",
"       chloral hydrate",
"      </a>",
"      , no medications are labeled for use for insomnia in children by the United States Food and Drug Administration. The array of medications that are currently prescribed in clinical practice for childhood sleep disturbances appears to be based largely on clinical experience, empirical data derived from adults, or small case series of medication use.",
"     </li>",
"     <li>",
"      Medication should be viewed in the context of the child's medical history and developmental age, and should be considered only when appropriately implemented behavioral interventions are not effective.",
"     </li>",
"     <li>",
"      The choice of medication for any child with a sleep disorder should be determined by the specific sleep diagnosis, weighing the relative risks and benefits. For example, agents with an immediate onset of action and short half-life are generally used for sleep onset insomnia, while a longer half-life and duration of action may assist with maintenance of sleep but may result in morning \"hangover\", daytime sleepiness, and compromised daytime functioning. While a discussion of specific hypnotic medications is beyond the scope of this chapter, recent reviews may be helpful in guiding the clinician [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36806/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleep problems with behavioral origins (behavioral insomnias of childhood) occur in 20 to 30 percent of children, and are especially common in children with medical, neurodevelopmental, or psychiatric disorders. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The sleep onset association subtype of Behavioral Insomnia is most common in infants and toddlers, and is characterized by prolonged night waking, requiring parental intervention to restore sleep. It occurs when the child learns to associate falling asleep with specific experiences, such as being rocked or fed. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Sleep onset association subtype'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The limit-setting subtype of Behavioral Insomnia is a disorder most common in children who are preschool-aged and older, and is characterized by active resistance, verbal protests, and repeated demands at bedtime. This disorder most commonly develops from a caregiver's inability or unwillingness to set consistent bedtime rules and enforce a regular bedtime. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Limit-setting subtype'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Behavioral intervention strategies, including bedtime routines, systematic ignoring, bedtime fading, positive reinforcement, and parental education, are highly effective in treating behavioral insomnias in children. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Behavioral interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An integral part of the bedtime routine is the institution of a bedtime and sleep schedule that ensures a developmentally appropriate amount of sleep. A consistent nightly bedtime will help to set the circadian clock and enable the child to fall asleep more easily. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Bedtime routines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of primary insomnia in older children and adolescents usually involves behavioral interventions that resemble those used in adults. Establishing a consistent sleep schedule is also important for older children and adolescents, for whom poor sleep hygiene is a common cause of sleep problems (",
"      <a class=\"graphic graphic_table graphicRef52760 \" href=\"mobipreview.htm?39/24/40331\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Older children and adolescents'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13290?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of insomnia\", section on 'Behavioral therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharmacologic therapy for the treatment of childhood insomnia is not a first-line treatment and should always be combined with behavioral therapy. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Pharmacologic interventions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Academy of Sleep Medicine. International classification of sleep disorders, 2nd ed: Diagnostic and coding manual, American Academy of Sleep Medicine, Westchester, IL 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36806/abstract/2\">",
"      Burnham MM, Goodlin-Jones BL, Gaylor EE, Anders TF. Nighttime sleep-wake patterns and self-soothing from birth to one year of age: a longitudinal intervention study. J Child Psychol Psychiatry 2002; 43:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36806/abstract/3\">",
"      Kerr S, Jowett S. Sleep problems in pre-school children: a review of the literature. Child Care Health Dev 1994; 20:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36806/abstract/4\">",
"      Owens JA, Spirito A, McGuinn M, Nobile C. Sleep habits and sleep disturbance in elementary school-aged children. J Dev Behav Pediatr 2000; 21:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36806/abstract/5\">",
"      Johnson EO, Roth T, Schultz L, Breslau N. Epidemiology of DSM-IV insomnia in adolescence: lifetime prevalence, chronicity, and an emergent gender difference. Pediatrics 2006; 117:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36806/abstract/6\">",
"      Fisher A, van Jaarsveld CH, Llewellyn CH, Wardle J. Genetic and environmental influences on infant sleep. Pediatrics 2012; 129:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36806/abstract/7\">",
"      Sadeh, A, Lavie, P, Scher, A. Maternal perceptions of temperament of sleep-disturbed toddlers. Early Educ Dev 1994; 5:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36806/abstract/8\">",
"      Mindell JA, Kuhn B, Lewin DS, et al. Behavioral treatment of bedtime problems and night wakings in infants and young children. Sleep 2006; 29:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36806/abstract/9\">",
"      Morgenthaler TI, Owens J, Alessi C, et al. Practice parameters for behavioral treatment of bedtime problems and night wakings in infants and young children. Sleep 2006; 29:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36806/abstract/10\">",
"      Wolfson A, Lacks P, Futterman A. Effects of parent training on infant sleeping patterns, parents' stress, and perceived parental competence. J Consult Clin Psychol 1992; 60:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36806/abstract/11\">",
"      Foley LS, Maddison R, Jiang Y, et al. Presleep activities and time of sleep onset in children. Pediatrics 2013; 131:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36806/abstract/12\">",
"      Scott G, Richards MP. Night waking in infants: effects of providing advice and support for parents. J Child Psychol Psychiatry 1990; 31:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36806/abstract/13\">",
"      Owens JA, Babcock D, Blumer J, et al. The use of pharmacotherapy in the treatment of pediatric insomnia in primary care: rational approaches. A consensus meeting summary. J Clin Sleep Med 2005; 1:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36806/abstract/14\">",
"      Owens JA. Pharmacotherapy of pediatric insomnia. J Am Acad Child Adolesc Psychiatry 2009; 48:99.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6353 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-B6CE745EC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_60_36806=[""].join("\n");
var outline_f35_60_36806=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Behavioral insomnia of childhood",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Sleep onset association subtype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Limit-setting subtype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Primary (psychophysiologic) insomnia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Transient forms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Developmental history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Behavioral assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      BEHAVIORAL INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Bedtime routines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Systematic ignoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Bedtime fading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Positive reinforcement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Parent education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OLDER CHILDREN AND ADOLESCENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PHARMACOLOGIC INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6353\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6353|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/24/40331\" title=\"table 1\">",
"      Sleep hygiene child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5929?source=related_link\">",
"      Assessment of sleep disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9561?source=related_link\">",
"      Types of insomnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_60_36807="Cardiac catheterization techniques: Normal hemodynamics";
var content_f35_60_36807=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiac catheterization techniques: Normal hemodynamics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/60/36807/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/60/36807/contributors\">",
"     Morton J Kern, MD, FSCAI, FAHA, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/60/36807/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/60/36807/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/60/36807/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/60/36807/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/60/36807/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamic data have always been, and remain, an integral part of all cardiovascular observations. Significant advances in both surgical and nonsurgical techniques for heart disease have been established in the last decade, in large part due to innovations both within and outside the cardiac catheterization laboratory. Many difficult forms of heart disease can now be readily confirmed with the improvement in two-dimensional and Doppler echocardiographic techniques. However, given the nature of clinical testing, there will always be suboptimal noninvasive examinations or patients in whom such testing cannot be performed. Thus, the catheterization laboratory remains critical to accurate measurements and the establishment of diagnoses. The presence of coexisting hemodynamic abnormalities in patients with coronary artery disease, myocardial infarction, or peripheral vascular disease cannot be established without direct information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VASCULAR ACCESS AND SPECIAL CATHETERIZATION TECHNIQUES FOR OBTAINING HEMODYNAMIC DATA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine catheter access is obtained from the femoral artery and vein in most situations. The radial artery (and when needed, brachial vein) approach has gained acceptance and demonstrated reduced bleeding complications relative to femoral artery access. Many laboratories now use radial access as the default approach for routine cardiac cath.",
"   </p>",
"   <p>",
"    Nonetheless, there are a variety of special access techniques which may be required for optimal hemodynamic assessment (",
"    <a class=\"graphic graphic_table graphicRef77757 \" href=\"mobipreview.htm?6/14/6379\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36807/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transseptal access to the left atrium or ventricle is most often employed when prosthetic valves are located either in the aortic or mitral positions. Direct left atrial pressure measurement via the transseptal approach is also highly desirable, if not critical, to accurate decision making in conditions such as mitral stenosis, in which the pulmonary capillary wedge pressure is unreliable as a surrogate for the left atrial pressure. Under fluoroscopic guidance the transseptal access is obtained using a Brockenbrough catheter that is passed through the atrial septum over a needle that is used to puncture the septum at the fossa ovalis. This technique is commonly used for accurate assessment of mitral valve disease and as access for mitral balloon valvuloplasty.",
"     </li>",
"     <li>",
"      Direct left ventricular puncture through the left ventricular apex via the fifth intercostal space using echo-guided needle positioning is rarely used, but needed in patients with both aortic and mitral prosthetic valves. This technique is rarely used and carries significant excess risk.",
"     </li>",
"     <li>",
"      Catheters placed into the pericardial space when pericardial effusion is present may be necessary when determination of pericardial pressure is required for the assessment of clinical tamponade or congestive heart failure symptoms or hypotension of unexplained etiology.",
"     </li>",
"     <li>",
"      In some situations, special catheters are necessary for accurate recording. As an example, in the assessment of aortic stenosis, high fidelity manometer-tipped pressure catheters (or pressure sensor guidewire) are available to record small differences between aortic and left ventricular pressure. This technique can identify aortic gradients with improved precision when compared to fluid filled transducer systems. Double lumen catheters are also available. Improved ease of use these specialized catheters may gain future widespread application.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ROUTINE HEMODYNAMIC MEASUREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine hemodynamic measurements are obtained from the aorta (Ao), left ventricle (LV), right ventricle (RV), right atrium (RA), pulmonary artery (PA), and the pulmonary artery wedge position (for pulmonary capillary wedge pressure or PCWP); the last is usually equivalent to the left atrial (LA) pressure (",
"    <a class=\"graphic graphic_figure graphicRef70695 \" href=\"mobipreview.htm?23/57/24470\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The aortic pressure is often measured when the catheter is in the femoral artery. However, the pressure obtained from the femoral artery does not accurately reflect central aortic pressure; it may be higher because of reflected waves within the arterial system. In general, an overshoot of &lt;20 mmHg relative to central aortic pressure is to be expected and is satisfactory for most clinical situations. When this overshoot is excessive, however, or when there is evidence of peripheral vascular disease, a second arterial catheter positioned within the central aorta above the aortic valve may be required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36807/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pressures in two or more chambers are simultaneously measured to establish the presence of pressure gradients across various structures (eg, valves). As examples, simultaneous Ao and LV pressures are obtained to establish a gradient across the aortic valve, while simultaneous LV and LA (or PCWP) pressures will establish a gradient across the mitral valve (",
"    <a class=\"graphic graphic_figure graphicRef70695 \" href=\"mobipreview.htm?23/57/24470\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef57331 \" href=\"mobipreview.htm?42/48/43776\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef78334 \" href=\"mobipreview.htm?36/14/37098\">",
"     waveform 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NORMAL WAVEFORMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of waveforms from the different cardiac structures is essential for understand normal hemodynamics and to detect and quantify valvular, myocardial, and pericardial abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44199?source=see_link\">",
"     \"Pulmonary artery catheterization: Interpretation of tracings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Right atrium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The right atrial pressure waveform consists of two major positive deflections, the \"a\" and \"v\" waves (",
"    <a class=\"graphic graphic_waveform graphicRef74628 \" href=\"mobipreview.htm?14/47/15089\">",
"     waveform 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef78334 \" href=\"mobipreview.htm?36/14/37098\">",
"     waveform 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The \"a\" wave results from right atrial contraction and immediately follows the P wave on the surface ECG.",
"     </li>",
"     <li>",
"      Following the a wave and right atrial contraction, the pressure declines, defining the \"x\" descent. A small positive deflection, known as the \"c\" wave, may be seen reflecting closure of the tricuspid valve. Thereafter, the \"x\" descent continues as right atrial pressure declines due to right atrial relaxation.",
"     </li>",
"     <li>",
"      After full atrial relaxation and the nadir of the \"x\" descent, right atrial pressure rises due to increased volume from peripheral venous return. With right ventricular systole and the rapid increase in right ventricular pressure, the tricuspid valve closes. The increasing right atrial pressure during right ventricular systole is the \"v\" wave; it reaches maximal amplitude just prior to the opening of the tricuspid valve. When the pressure in the right ventricle falls below that of the right atrium the tricuspid valve opens.",
"     </li>",
"     <li>",
"      After tricuspid valve opening, at the beginning of right ventricular diastole, the pressure in the right atrium rapidly falls, defining the \"y\" descent. After the \"y\" descent, the pressure in the right atrium equals the right ventricular end diastolic pressure since the tricuspid valve is opened; it slowly increases as the right ventricle fills.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The normal mean right atrial pressure is between 1 and 8 mmHg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Jugular venous pulsations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The jugular venous pulse closely reflects changes in right atrial pressure, and also parallels changes observed in the vena cavae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36807/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The variations in pressure within the right atrium are reflected principally by a change in volume for the venous system.",
"   </p>",
"   <p>",
"    It is thought that the pulse wave transmission from the right atrium to the jugular veins has the least disparity for pressure waves which are positive and conducted more rapidly, as compared to negative more slowly conducted pressure waves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36807/abstract/6\">",
"     6",
"    </a>",
"    ]. The venous pulse \"a\" and \"c\" waves have an average delay from the right atrium of approximately 60 msec, while the \"v\" wave delay is 80 msec; by comparison, the \"y\" trough delay is 90 msec, and the \"x\" trough 110 msec [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36807/abstract/6\">",
"     6",
"    </a>",
"    ]. It also requires 60 msec for the right atrial \"a\" wave to reach the right ventricle and cause a positive defection in this chamber. These delays should be considered when examining the jugular venous pulse, as well as inferior vena caval pressure waves as a reflection of right atrial pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36807/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Carotid arterial pressure waves may induce artifact in jugular vein pulsations. This artifact can be recognized by an irregular pulsation that often obscures the \"x\" descent. The irregular wave shows a carotid-like, contour with the dicrotic notch recognized in the middle of the \"x\" descent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36807/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Right ventricle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The right ventricular waveform consists of systole, a result of right ventricular contraction, and diastole occurring with right ventricular relaxation (",
"    <a class=\"graphic graphic_waveform graphicRef74628 \" href=\"mobipreview.htm?14/47/15089\">",
"     waveform 3",
"    </a>",
"    ). During right ventricular systole, the pressure rapidly rises; when it is higher than that of the right atrium, the tricuspid valve closes. When the pressure exceeds that of the pulmonary artery, the pulmonic valve opens. The systolic waveform is rapid in upstroke and rounded in morphology; it occurs simultaneously with or immediately after the QRS complex on the surface ECG. The peak or maximal amplitude of this waveform is the right ventricular systole pressure.",
"   </p>",
"   <p>",
"    At the end of systole there is right ventricular relaxation and a rapid fall in pressure back to baseline. This is the initiation of right ventricular diastole. When the pressure in the right ventricle is lower than that of the pulmonary artery, the pulmonic valve closes. As the right ventricular pressure falls further, it becomes lower than that of the right atrium and the tricuspid valve opens.",
"   </p>",
"   <p>",
"    Diastole consists of three periods generating three waveforms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first period, occurring at the onset of tricuspid valve opening, produces an early rapid filling wave during which approximately 60 percent of ventricular filling occurs.",
"     </li>",
"     <li>",
"      Following this is a slow filling period, accounting for approximately 15 percent of ventricular filling.",
"     </li>",
"     <li>",
"      Right atrial systole, which accounts for approximately 25 percent of right ventricular diastolic filling, produces an \"a\" wave that is simultaneous with and identical in morphology and amplitude to the \"a\" wave on the right atrial pressure tracing, since the tricuspid valve is opened and creates essentially one chamber. The pressure at the end of the \"a\" wave is termed the right ventricular end-diastolic pressure (RVEDP).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The right ventricular pressure tracing is similar to that generated by the left ventricle except that the pressures are lower.",
"   </p>",
"   <p>",
"    The normal right ventricular diastolic pressure is 1 to 8 mmHg and the peak systolic pressure is 15 to 30 mmHg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulmonary artery waveform reflects systolic pressure resulting from rapid flow of blood into the pulmonary artery from the right ventricle during right ventricular systole. Since the pulmonic valve is opened, the waveform in systole is identical in morphology and amplitude to that of right ventricular systole.",
"   </p>",
"   <p>",
"    As right ventricular ejection ends, the pressure in the pulmonary artery falls in similar fashion to that in the right ventricle. However, as right ventricular pressure falls below that of the pulmonary artery, the pulmonic valve closes, resulting in an incisura, or dicrotic notch, on the downslope of the pressure tracing. Pressure in the pulmonary artery continues to fall gradually as blood flows through the pulmonary arteries and veins into the left side of the heart, reaching a nadir or the end-diastolic pulmonary artery pressure.",
"   </p>",
"   <p>",
"    The waveform of the pulmonary artery is similar in morphology to that of the aorta, but the pressure is lower.",
"   </p>",
"   <p>",
"    The normal pulmonary artery systolic pressure is 15 to 30 mmHg and the pulmonary artery diastolic pressure is 4 to 12 mmHg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pulmonary capillary wedge and left atrium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulmonary capillary wedge pressure (PCWP) has a waveform and amplitude that is similar to that of the left atrial pressure wave, but it is damped and delayed because of transmission through the capillary vessels (",
"    <a class=\"graphic graphic_waveform graphicRef53685 \" href=\"mobipreview.htm?41/26/42400\">",
"     waveform 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef78334 \" href=\"mobipreview.htm?36/14/37098\">",
"     waveform 2",
"    </a>",
"    ). The normal \"wedge\" and left atrial waveforms are similar in morphology to those of the right atrial pressure tracing, although the pressure is higher.",
"   </p>",
"   <p>",
"    The normal waveform consists of an \"a\" wave due to atrial contraction, a \"v\" wave reflecting left atrial filling during left ventricular contraction, a \"c\" wave (which may not be apparent on the PCWP tracing) due to mitral valve closure, and a \"x\" and \"y\" descent due to left atrial relaxation and left ventricular diastole, respectively. In the normal situation, the mean PCWP and end-diastolic pulmonary artery pressure are approximately equal.",
"   </p>",
"   <p>",
"    The normal mean left atrial pressure (and pulmonary capillary wedge pressure) is between 4 and 12 mmHg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Left ventricle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The components of the left ventricular pressure waveform are similar to that of the right ventricular waveform except the systolic and diastolic pressures are appropriately higher (",
"    <a class=\"graphic graphic_waveform graphicRef56029 \" href=\"mobipreview.htm?43/39/44671\">",
"     waveform 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef78334 \" href=\"mobipreview.htm?36/14/37098\">",
"     waveform 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left ventricular systole causes a rapid increase in left ventricular pressure. When it becomes higher than that of the left atrium, the mitral valve closes. The pressure continues to rise; when it exceeds that of the aorta, the aortic valve opens.",
"     </li>",
"     <li>",
"      After the peak systolic pressure, left ventricular diastole begins and there is a rapid fall in pressure. When the left ventricular pressure falls to a level below that of the aorta, the aortic valve closes. As the left ventricular pressure continues to fall, it becomes lower than that of the left atrium and the mitral valve opens, resulting in left atrial emptying into the left ventricle, or ventricular diastole (",
"      <a class=\"graphic graphic_waveform graphicRef61351 \" href=\"mobipreview.htm?19/28/19907\">",
"       waveform 6",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar to pressure changes in the right ventricle, left ventricular diastole consists of three periods: rapid filling; slow filling; and atrial contraction (",
"    <a class=\"graphic graphic_figure graphicRef75205 \" href=\"mobipreview.htm?38/28/39374\">",
"     figure 2",
"    </a>",
"    ). The pressure immediately after left atrial contraction, the \"a\" wave, is the left ventricular end-diastolic pressure (LVEDP). Since the mitral valve is opened, the \"a\" wave is identical to that seen on the left atrial waveform.",
"   </p>",
"   <p>",
"    The normal LVEDP is 4 to 12 mmHg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Left ventricular end-diastolic pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular end-diastolic filling pressure (LVEDP) is often indicative of the hemodynamic health of the left ventricle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36807/abstract/8\">",
"     8",
"    </a>",
"    ]. Left ventricular pressure is available for examination from nearly every catheterization. Right heart catheterization and measurement of the pulmonary capillary wedge pressure in most patients with coronary artery disease has been replaced by examining the LVEDP before contrast ventriculography.",
"   </p>",
"   <p>",
"    The LVEDP immediately precedes the beginning of isometric ventricular contraction on the left ventricular pressure pulse. This point, also known as the \"Z\" point, is situated on the downslope of the left ventricular \"a\" wave and marks the crossing over of left atrial and left ventricular pressures. This point is coincident with the R wave on the surface ECG (",
"    <a class=\"graphic graphic_waveform graphicRef56029 \" href=\"mobipreview.htm?43/39/44671\">",
"     waveform 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef78334 \" href=\"mobipreview.htm?36/14/37098\">",
"     waveform 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Identification of the true LVEDP can at times be difficult. There may be several different inflection points of the LVEDP; the \"a\" wave can show a changing pressure since the multiple-holed pigtail catheter which is usually placed into the left ventricle for pressure measurements and radiographic contrast media injection may move across the aortic valve with inspiration or heart motion, thereby causing the LVEDP to be artifactually higher. This artifact can be detected by the pressure waveform and identification of the lowest left ventricular pressure at the initiation of diastole. Thus, stability of the catheter and acquisition of a reliable pressure wave is required for the accurate interpretation of LVEDP.",
"   </p>",
"   <p>",
"    Interpretation of the LVEDP waveform has contributed to our understanding of left ventricular contraction and relaxation (",
"    <a class=\"graphic graphic_waveform graphicRef56029 \" href=\"mobipreview.htm?43/39/44671\">",
"     waveform 5",
"    </a>",
"    ) and (",
"    <a class=\"graphic graphic_figure graphicRef79441 \" href=\"mobipreview.htm?33/22/34146\">",
"     figure 3",
"    </a>",
"    ). The pressure wave is a reflection of ventricular compliance and therefore indirectly represents the clinical conditions which affect ventricular performance. As an example, early clinical studies of hypertrophic cardiomyopathy emphasized the intraventricular gradient, while recent echocardiographic information has documented abnormal diastolic function with prolonged left ventricular isovolumetric relaxation phases and impaired diastolic filling. Diastolic function and systolic performance can be improved in patients with hypertrophic cardiomyopathy with a calcium channel blocker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36807/abstract/9\">",
"     9",
"    </a>",
"    ]. The substantial hemodynamic and clinical improvement corresponds to normalization of the left ventricular diastolic pressure curve. The LVEDP is normally &lt;12 mmHg. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28600?source=see_link\">",
"     \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Abnormal LVEDP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The LVEDP may be elevated when the left ventricle experiences excessive diastolic volume overload, as occurs, for example, with mitral or aortic valvular regurgitation or high-volume shunting at or distal to the ventricular septum. Impairment of myocardial contractility also alters the diastolic pressure-volume relationship and shifts the end-diastolic pressure point upward. Conditions of concentric hypertrophy due to hypertension or valvular stenosis, restrictive or infiltrative cardiomyopathy, or other diseases of the ventricular muscle produce a stiffer chamber and thus alter the pressure-volume curve, thereby elevating the LVEDP (",
"    <a class=\"graphic graphic_waveform graphicRef53250 \" href=\"mobipreview.htm?42/16/43270\">",
"     waveform 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the routine examination of the LVEDP, careful inspection of the waveform in diastole provides important information about left ventricular diastolic function. Myocardial relaxation abnormalities may be suggested by observing the trend of pressure during diastasis. As an example, a low LVEDP with a continuing decline of pressure over the mid-diastolic period, with the pressure nadir occurring midway through the diastolic period, suggests impaired myocardial relaxation that may be found in patients with severe left ventricular hypertrophy. In addition, with left ventricular hypertrophy and a \"stiff\" ventricle, an abnormally tall \"a\" wave resulting in a marked elevation of LVEDP may occur, although the diastolic pressure prior to atrial contraction can be normal (",
"    <a class=\"graphic graphic_figure graphicRef79441 \" href=\"mobipreview.htm?33/22/34146\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef53250 \" href=\"mobipreview.htm?42/16/43270\">",
"     waveform 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients with an inducible obstructive hypertrophic cardiomyopathy may have an abnormal LVEDP waveform which resembles that seen in left ventricular hypertrophy due to hypertension. An abnormal LVEDP waveform may develop with a Valsalva maneuver or induced premature ventricular contractions that result in the development of an intraventricular gradient (",
"    <a class=\"graphic graphic_waveform graphicRef62664 \" href=\"mobipreview.htm?33/2/33832\">",
"     waveform 8",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28600?source=see_link\">",
"     \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3455460\">",
"    <span class=\"h2\">",
"     Aorta",
"    </span>",
"    &nbsp;&mdash;&nbsp;The waveform generated in the aorta is similar to that seen in the pulmonary artery except that the systolic and diastolic pressures are significantly higher. The systolic wave is similar to that of the left ventricular systolic wave as the aortic valve is opened and the two structures are in direct communication. When left ventricular pressure falls to a level below that of the aorta, the aortic valve closes and produces the dicrotic notch on the aortic pressure tracing. A gradual fall in aortic pressure continues as blood flows from the aorta to the peripheral vessels, until the end-diastolic pressure is reached (",
"    <a class=\"graphic graphic_waveform graphicRef57045 \" href=\"mobipreview.htm?2/27/2480\">",
"     waveform 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef66480 \" href=\"mobipreview.htm?29/54/30561\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70695 \" href=\"mobipreview.htm?23/57/24470\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are gender differences in the central aortic pressure waveform. One study reported that women had a prominent secondary late systolic peak in the aortic pressure wave and as a result had a higher augmentation index (the difference between early and late pressure peaks divided by the pulse pressure), an index of pulsatile afterload (",
"    <a class=\"graphic graphic_figure graphicRef66212 \" href=\"mobipreview.htm?43/15/44286\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36807/abstract/10\">",
"     10",
"    </a>",
"    ]. Women also had a lower subendocardial viability index (the ratio of diastolic to systolic time integral) reflecting a reduction in subendocardial blood flow; this was largely the result of a higher heart rate and shorter diastolic period. These differences may explain the greater degree of age-related left ventricular hypertrophy and the higher incidence of congestive heart failure after myocardial infarction despite smaller infarctions in women compared to men.",
"   </p>",
"   <p>",
"    Body height also alters the aortic waveform. Short stature is associated with a faster heart rate, shortened return times for reflected waveforms, and increased augmentation of the primary systolic pulse, but no change in mean blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36807/abstract/11\">",
"     11",
"    </a>",
"    ]. These factors cause a stiffening of the aorta in late systole (which increases the stroke and minute work of the left ventricle) and a reduction in diastolic pressure and duration (which reduces coronary artery blood flow). These findings may explain the association between short stature and an increased risk for coronary heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36807/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SIMULTANEOUS LEFT VENTRICULAR AND RIGHT VENTRICULAR END-DIASTOLIC PRESSURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insights into the diagnosis of left ventricular dysfunction may be appreciated by examination of simultaneously displayed left and right ventricular pressure waveforms. Abnormalities of ventricular contraction and relaxation, ventricular conduction abnormalities, and",
"    <span class=\"nowrap\">",
"     restrictive/constrictive",
"    </span>",
"    pathophysiologic states are often evident (",
"    <a class=\"graphic graphic_waveform graphicRef53250 \" href=\"mobipreview.htm?42/16/43270\">",
"     waveform 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Abnormalities of cardiac rhythm can produce marked distortions in the timing relationship between left ventricular and right ventricular pressures (",
"    <a class=\"graphic graphic_waveform graphicRef54899 \" href=\"mobipreview.htm?3/39/3700\">",
"     waveform 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef66693 \" href=\"mobipreview.htm?19/37/20055\">",
"     waveform 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef82603 \" href=\"mobipreview.htm?5/7/5235\">",
"     figure 6",
"    </a>",
"    ). As an example, a paced rhythm from a right ventricular endocardial pacemaker delays and skews the relaxation period of left ventricle pressure, resulting in overlap of the left ventricular pressure downslope with that of the right ventricular pressure, an unusual alignment of the diastolic pressures (",
"    <a class=\"graphic graphic_waveform graphicRef54899 \" href=\"mobipreview.htm?3/39/3700\">",
"     waveform 10",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LEFT VENTRICULAR COMPLIANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The curvilinear relationship between stroke work and LVEDP has been commonly called the left ventricular function curve; it is a measure of the performance of ventricular activity. The ventricular function curves are shifted upward by positive inotropic interventions and downward by those impairing inotropic activity. Afterload also may significantly influence the elevation or decline of the ventricular function curve.",
"   </p>",
"   <p>",
"    Compliance of the left ventricle is probably the major determinant of the LVEDP. Compliance is defined as the change in volume divided by the change in ventricular pressure (",
"    <a class=\"graphic graphic_figure graphicRef59748 \" href=\"mobipreview.htm?32/1/32797\">",
"     figure 7",
"    </a>",
"    ). Both ventricular volume and pressure must be measured simultaneously to compute compliance. The slope of the compliance curve is called stiffness, which is the inverse of compliance.",
"   </p>",
"   <p>",
"    Compliance tends to decrease in chronic conditions involving myocardial hypertrophy, restrictive cardiomyopathy, or other infiltrative processes (",
"    <a class=\"graphic graphic_figure graphicRef79248 \" href=\"mobipreview.htm?17/22/17774\">",
"     figure 8",
"    </a>",
"    ). In patients with cardiac disease, LVEDP may be altered as myocardial ischemia is provoked. As an example, one study of normal subjects and patients with coronary artery disease with and without angina reported the LVEDP at rest, during rapid atrial pacing, and upon immediate termination of pacing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36807/abstract/13\">",
"     13",
"    </a>",
"    ]. In contrast to normal individuals, left ventricular pressure was elevated in patients with pacing-induced myocardial ischemia, while patients without pacing-induced ischemia had a smaller change in LVEDP. The compliance shift due to ischemia altered the LVEDP (",
"    <a class=\"graphic graphic_figure graphicRef59748 \" href=\"mobipreview.htm?32/1/32797\">",
"     figure 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although information about ventricular performance, especially diastolic function, can be gleaned from careful examination of the LVEDP waveform, artifacts of pressure waveforms should be identified to avoid confusion with true pathophysiologic responses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PULMONARY CAPILLARY WEDGE PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulmonary artery wedge pressure has been commonly accepted as an accurate reflection of left atrial pressure; it is often used in the assessment of mitral valve disease. The normal pulmonary capillary wedge pressure (PCWP) is obtained with an 8F balloon-tipped pulmonary artery catheter that is passed through the right heart and pulmonary artery with the balloon inflated after appropriate flushing of the fluid filled transducer system.",
"   </p>",
"   <p>",
"    Normal left atrial pressure wave timing precedes PCWP by 40 to 120 msec and often has a slightly higher pressure due to damped transmission of pressure backward through the pulmonary capillaries. The two tracings are nearly identical in waveform [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36807/abstract/14\">",
"     14",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_waveform graphicRef53685 \" href=\"mobipreview.htm?41/26/42400\">",
"     waveform 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Simultaneous recording of the left ventricular pressure and Doppler mitral inflow velocity illustrate the early and late filling phases of flow through the mitral valve, corresponding to the \"v\" and \"a\" waves, respectively (",
"    <a class=\"graphic graphic_waveform graphicRef61351 \" href=\"mobipreview.htm?19/28/19907\">",
"     waveform 6",
"    </a>",
"    ). Peak early filling represents the early ventricular filling \"v\" wave of the left atrial and pulmonary capillary wedge pressures. The peak atrial filling, producing the \"a\" wave, is the flow velocity increase due to atrial contraction. The timing of these flow velocities corresponds to the pressure changes which are important for the hemodynamic assessment of mitral valve disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36807/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     PCWP fidelity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the PCWP is generally accepted as a measurement of left atrial pressure in the examination of mitral valve hemodynamics, pulmonary capillary wedge pressure fidelity is at times not satisfactory. An overly damped pulmonary wedge pressure may provide an equivalent mean pressure to left atrial pressure; however, the phasic wave forms may obscure the precise diagnosis of mitral stenosis (",
"    <a class=\"graphic graphic_waveform graphicRef53685 \" href=\"mobipreview.htm?41/26/42400\">",
"     waveform 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef73647 \" href=\"mobipreview.htm?8/18/8482\">",
"     waveform 12",
"    </a>",
"    ). If a diagnosis and accurate measurement is necessary and catheter manipulation and flushing of the transducer system does not improve the quality of the waveform, direct left atrial pressure should be measured with a transseptal catheter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TIMING OF HEMODYNAMICS WITH THE ECG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamic data require examination not only of individual pressure waves, but also their timing to events on the ECG, particularly the QRS complex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36807/abstract/8\">",
"     8",
"    </a>",
"    ]. Correct interpretation of normal right heart pressure waveforms and careful examination of the unusual right heart hemodynamics and their timing in the cardiac cycle may reveal unanticipated pathophysiologic mechanisms.",
"   </p>",
"   <p>",
"    Abnormalities of the waveforms can occur in the presence of arrhythmia or ventricular pacing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36807/abstract/3,15\">",
"     3,15",
"    </a>",
"    ]. This must be considered when interpreting hemodynamic data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/53/35667?source=see_link\">",
"       \"Patient information: Cardiac catheterization (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6059272\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamic data may be required to assess either the cause or severity of a particular clinical presentation attributable to a cardiac abnormality. Echocardiographic evaluation of the heart has replaced and decreased the role of invasive hemodynamic evaluation. However, periodically there are suboptimal noninvasive examinations, as well as cases in which the noninvasive data is felt to be potentially erroneous. Thus, hemodynamic evaluation in the catheterization laboratory remains an important resource.",
"   </p>",
"   <p>",
"    The following are normal hemodynamic findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The normal mean right atrial pressure is between 1 and 8 mmHg. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Right atrium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The normal right ventricular diastolic pressure is 1 to 8 mmHg and the peak systolic pressure is 15 to 30 mmHg. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Right ventricle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The normal pulmonary artery systolic pressure is 15 to 30 mmHg and the pulmonary artery diastolic pressure is 4 to 12 mmHg. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pulmonary artery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The normal mean left atrial pressure (and pulmonary capillary wedge pressure) is between 4 and 12 mmHg. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pulmonary capillary wedge and left atrium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The normal LVEDP is 4 to 12 mmHg. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Left ventricle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the presence of a normal pulmonic valve, the peak right ventricular and pulmonary artery systolic pressures are the same. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pulmonary artery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the presence of a normal aortic valve, the peak left ventricular and aortic systolic pressures are the same. (See",
"      <a class=\"local\" href=\"#H3455460\">",
"       'Aorta'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Cardiac Catheterization and Angiography, 3rd ed, Grossman, W (Ed) (Eds), Lea &amp; Febiger, Philadelphia 1986.",
"    </li>",
"    <li>",
"     Diagnostic and Therapeutic Cardiac Catheterization, Pepine, CJ (Ed) (Eds), Williams &amp; Wilkins, Baltimore 1989.",
"    </li>",
"    <li>",
"     Kern MJ, Feldman T, Bitar S. Hemodynamic Data. In: The Cardiac Catheterization Handbook, 5th ed, Kern MJ.  (Ed), Mosby-Year Book, St. Louis 2011. p.126.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36807/abstract/4\">",
"      Morgan BC, Abel FL, Mullins GL, Guntheroth WG. Flow patterns in cavae, pulmonary artery, pulmonary vein, and aorta in intact dogs. Am J Physiol 1966; 210:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36807/abstract/5\">",
"      BRECHER GA, HUBAY CA. Pulmonary blood flow and venous return during spontaneous respiration. Circ Res 1955; 3:210.",
"     </a>",
"    </li>",
"    <li>",
"     Willems, J, Roelandt, J, Kesteloot, H. The jugular venous pulse tracing. Proc Vth European Cong Cardiol Sept 1968. p.433.",
"    </li>",
"    <li>",
"     Tavel ME. Normal sounds and pulses: Relationships and intervals between the various events. In: Clinical Phonocardiography and External Pulse Recording, 2nd, Year Book Medical Publishers, Chicago 1972. p.35.",
"    </li>",
"    <li>",
"     Kern MJ. Avoiding pitfalls in hemodynamic diagnosis. In: ACC Current Journal Review, Knoebel SB (Ed) (Ed), 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36807/abstract/9\">",
"      Lorell BH, Paulus WJ, Grossman W, et al. Improved diastolic function and systolic performance in hypertrophic cardiomyopathy after nifedipine. N Engl J Med 1980; 303:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36807/abstract/10\">",
"      Hayward CS, Kelly RP. Gender-related differences in the central arterial pressure waveform. J Am Coll Cardiol 1997; 30:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36807/abstract/11\">",
"      Smulyan H, Marchais SJ, Pannier B, et al. Influence of body height on pulsatile arterial hemodynamic data. J Am Coll Cardiol 1998; 31:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36807/abstract/12\">",
"      Kannam JP, Levy D, Larson M, Wilson PW. Short stature and risk for mortality and cardiovascular disease events. The Framingham Heart Study. Circulation 1994; 90:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36807/abstract/13\">",
"      Parker JO, Ledwich JR, West RO, Case RB. Reversible cardiac failure during angina pectrois: hemodynamic effects of atrial pacing in coronary artery disease. Circulation 1969; 39:745.",
"     </a>",
"    </li>",
"    <li>",
"     Kern MJ. Hemodynamic Rounds: Interpretation of Cardiac Pathophysiology from Pressure Waveform Analysis, Wiley-Liss, New York 1993. p.41.",
"    </li>",
"    <li>",
"     Hemodynamic Rounds: Interpretation of Pathophysiology from Pressure Waveform Analysis, 3rd ed, Kern MJ, Goldstein J, Lim M (Eds), Wiley-Liss, New York 2010.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1515 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-5849588C53-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_60_36807=[""].join("\n");
var outline_f35_60_36807=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6059272\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VASCULAR ACCESS AND SPECIAL CATHETERIZATION TECHNIQUES FOR OBTAINING HEMODYNAMIC DATA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ROUTINE HEMODYNAMIC MEASUREMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NORMAL WAVEFORMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Right atrium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Jugular venous pulsations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Right ventricle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pulmonary capillary wedge and left atrium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Left ventricle",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Left ventricular end-diastolic pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Abnormal LVEDP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3455460\">",
"      Aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SIMULTANEOUS LEFT VENTRICULAR AND RIGHT VENTRICULAR END-DIASTOLIC PRESSURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LEFT VENTRICULAR COMPLIANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PULMONARY CAPILLARY WEDGE PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PCWP fidelity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TIMING OF HEMODYNAMICS WITH THE ECG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6059272\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1515\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1515|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/57/24470\" title=\"figure 1\">",
"      Normal cardiac hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/28/39374\" title=\"figure 2\">",
"      Normal LV hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/22/34146\" title=\"figure 3\">",
"      LV pressure diastolic dysfunct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/54/30561\" title=\"figure 4\">",
"      Normal LV Ao pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/15/44286\" title=\"figure 5\">",
"      Gender and aortic waveform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/7/5235\" title=\"figure 6\">",
"      RA RV pressure junct rhythm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/1/32797\" title=\"figure 7\">",
"      LV diastolic pressure volume relationship",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/22/17774\" title=\"figure 8\">",
"      LV diastolic pressure volume relationship 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1515|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/14/6379\" title=\"table 1\">",
"      Specialized cath techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1515|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?42/48/43776\" title=\"waveform 1\">",
"      LV - aorta pullback",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?36/14/37098\" title=\"waveform 2\">",
"      Normal RA and PCW and LV pressures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?14/47/15089\" title=\"waveform 3\">",
"      Right sided pressures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?41/26/42400\" title=\"waveform 4\">",
"      LA PCW pressures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?43/39/44671\" title=\"waveform 5\">",
"      Normal LV pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?19/28/19907\" title=\"waveform 6\">",
"      LV pressure echo Doppler MV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?42/16/43270\" title=\"waveform 7\">",
"      LV RV diastolic pressures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?33/2/33832\" title=\"waveform 8\">",
"      Pressures variable obstr HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?2/27/2480\" title=\"waveform 9\">",
"      Central periph aortic pressures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?3/39/3700\" title=\"waveform 10\">",
"      RA PA pressures pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?19/37/20055\" title=\"waveform 11\">",
"      RA PCW pressures VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?8/18/8482\" title=\"waveform 12\">",
"      LA PCWP mitral valve",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/53/35667?source=related_link\">",
"      Patient information: Cardiac catheterization (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44199?source=related_link\">",
"      Pulmonary artery catheterization: Interpretation of tracings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28600?source=related_link\">",
"      Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_60_36808="Parainfluenza viruses in children";
var content_f35_60_36808=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Parainfluenza viruses in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/60/36808/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/60/36808/contributors\">",
"     Flor M Munoz, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/60/36808/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/60/36808/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/60/36808/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/60/36808/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/60/36808/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/60/36808/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human parainfluenza viruses are important respiratory pathogens in children and adults. In infants and young children, parainfluenza viruses are the most common cause of lower respiratory tract infections after respiratory syncytial virus (RSV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Lower respiratory infections (eg, bronchiolitis, interstitial pneumonitis, pneumonia) are a leading cause of morbidity and mortality in infants during the first year of life in the United States and in children younger than the age of six years in developing countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/1\">",
"     1",
"    </a>",
"    ]. In adults, parainfluenza viruses generally cause mild upper respiratory infections (URIs) but can induce more severe disease in the elderly. Immunocompromised patients, particularly lung and hematopoietic cell transplant recipients can experience life-threatening lower respiratory tract infections with parainfluenza virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The virology, clinical manifestations, diagnosis, and treatment of parainfluenza viruses in children will be reviewed here. Infection with parainfluenza viruses in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/617?source=see_link\">",
"     \"Parainfluenza viruses in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parainfluenza viruses (PIV) are single-stranded, enveloped RNA viruses belonging to the genus paramyxovirus in the",
"    <em>",
"     Paramyxoviridae",
"    </em>",
"    family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/6\">",
"     6",
"    </a>",
"    ]. This family also includes human mumps, measles, and respiratory syncytial viruses and metapneumoviruses, as well as avian, bovine, and murine strains of these viruses.",
"   </p>",
"   <p>",
"    The virions are pleomorphic and range in diameter from 150 to 200 nm. The single strand of negative-sense RNA is 15,462 nucleotides in length and encodes six common viral proteins: the nucleocapsid protein (NP), the phosphoprotein (P), the matrix protein (M), the fusion glycoprotein (F), the hemagglutinin-neuramininidase glycoprotein (HN), and the RNA polymerase (L) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The HN and F proteins project through the lipid envelope and form the major antigenic targets for neutralizing antibody [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/8\">",
"       8",
"      </a>",
"      ]. Their hydrophobic tails project into the virion, where they interact with the M protein to aid in virus assembly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The nucleocapsid core is composed of NP, P, and L proteins in association with viral RNA. NP proteins bind tightly to the viral genome, creating a template for the RNA-dependent RNA polymerase composed of the P and L proteins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The HN glycoproteins are involved in attachment of the virus to the host cell via interactions with sialic acid residues on the cell surface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/11\">",
"     11",
"    </a>",
"    ]. This interaction allows the F protein to mediate virus-cell membrane fusion, which is required for nucleocapsid entry and infection of the host cell. The neuraminidase portion of the HN protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/11\">",
"     11",
"    </a>",
"    ] mediates budding of progeny virions from the surface of infected cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, each parainfluenza virus expresses at least one non-essential protein: PIV1 and PIV3 RNA encode short C proteins, PIV2 RNA encodes a V protein, and PIV 3 also expresses a D protein. The C and V proteins inhibit the host innate immune response (host cell antiviral responses) by suppressing the activity of type I interferons; the function of the D protein is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Viral serotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four major serotypes of human PIV (PIV-1, 2, 3, 4) have been described based upon complement fixation and hemagglutinating antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/4\">",
"     4",
"    </a>",
"    ]. Parainfluenza virus 5 (PIV-5) causes disease in animals (dogs, cats, pigs) but its role in human disease remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PIV-3 is the most prevalent serotype, with 90 to 100 percent of children demonstrating antibody responses by age five [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/16\">",
"     16",
"    </a>",
"    ]. In contrast, PIV-1 and PIV-2 infections are less common, with only 50 to 74 percent of five-year-olds demonstrating seropositivity. Fifty percent of six-year-old children and 70 to 90 percent of young adults have antibodies to PIV-4, despite the fact that infection is infrequently recognized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. PIV-1 particularly and PIV-2 are associated with croup in children, whereas PIV-3 is frequently associated with pneumonia and bronchiolitis in young infants. PIV-4 typically causes mild URI in both adults and children, but pneumonia and bronchiolitis have been described in infants and in children with underlying conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parainfluenza viruses (PIV) initially infect epithelial cells of the nose and oropharynx [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/21\">",
"     21",
"    </a>",
"    ] and then spread distally to the ciliated and alveolar cells of the bronchial epithelium of large and small airways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/22\">",
"     22",
"    </a>",
"    ]. Significant viral replication is seen in the nose and lungs 24 hours after infection, with viral replication peaking after two to five days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/23\">",
"     23",
"    </a>",
"    ]. Viral antigen can be detected in the apical portion of respiratory epithelial cells from days one to six of infection, with a decrease on day seven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extent of infection correlates well with disease: mild upper respiratory infections (URIs) are associated with limited infection of the nasopharynx, whereas more severe disease involves spread of infection to the large and small airways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/25\">",
"     25",
"    </a>",
"    ]. PIV-1 and PIV-2, which are associated with croup, tend to infect the larynx and upper trachea, whereas PIV-3, which is associated with bronchiolitis and pneumonia, infects the distal airways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/23\">",
"     23",
"    </a>",
"    ]. Progression to the lower respiratory tract and severity of disease depend upon factors such as virus titer in the upper respiratory tract, previous exposure to the specific virus, and genetic susceptibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/6,26,27\">",
"     6,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathologic examination of infected tissues in animal models of PIV infection suggests that minimal cellular or tissue damage is caused by direct viral effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/24\">",
"     24",
"    </a>",
"    ]. Similarly, PIV infection does not result in extensive cytopathic effect in in vitro models of respiratory airway epithelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/13,22,28\">",
"     13,22,28",
"    </a>",
"    ]. As is the case with other respiratory viruses, the host immune response plays an important role in the pathogenesis of PIV infection. PIV induces innate immune responses, CD8+ and CD4+ T-cell responses, interferon production, and local and systemic IgA and IgG responses, which contribute to the clearing of the virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/23,29\">",
"     23,29",
"    </a>",
"    ]. The increase in airway responsiveness that often is associated with PIV-3 infection (and other respiratory viruses, such as RSV) may result from IgE, increased stromal interleukin-11 production and enhanced acetylcholine release [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Preliminary experiments in animal models of infection suggest that a \"two-pronged\" approach to therapy, antiviral and antiinflammatory, may be useful in PIV-related illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parainfluenza viruses (PIV) are transmitted by direct person-to-person contact and through exposure to contaminated nasopharyngeal secretions through respiratory droplets and fomites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Incubation period",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period ranges from two to six days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human parainfluenza viruses are recovered most commonly in children younger than five years of age with upper respiratory infections (URIs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/3\">",
"     3",
"    </a>",
"    ]. Serologic studies have shown that as many as 50 percent of children have been infected with PIV-3 by their first birthday, whereas PIV-1 and PIV-2 most often affect preschool-aged children three to five years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PIV infections account for 20 to 40 percent of lower respiratory tract illnesses (eg, bronchiolitis, pneumonia) in children from which a virus is recoverable, and 2.8 per 1000 children with such infections require hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/36\">",
"     36",
"    </a>",
"    ]. PIV is responsible for approximately 30,000 (range 7600 to 48,000) pediatric hospitalizations annually in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/37\">",
"     37",
"    </a>",
"    ]. A study based upon the National Hospital Discharge survey from 1994 through 1997 estimated hospitalization rates due to PIV-1 to 3 to range from 1.9 to 12 per 1000 children younger than one year and from 0.5 to 2.0 per 1000 children ages one to four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/38\">",
"     38",
"    </a>",
"    ]. The highest overall hospitalization rates were for PIV-3, estimated at 0.48 to 2.6 per 1000 children. A population-based study in the US (2000 to 2004) estimated that PIV accounts for up to 7 percent of all hospitalizations for fever, acute respiratory illness, or both in children younger than 5 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/3\">",
"     3",
"    </a>",
"    ]; PIV3 is the cause of one-half of these hospitalizations.",
"   </p>",
"   <p>",
"    PIV infections occur throughout the world and throughout the year, with certain serotypes predominating during the spring or fall. In the United States, PIV-1 usually causes outbreaks biennially during the fall of odd-numbered years (",
"    <a class=\"graphic graphic_figure graphicRef56691 \" href=\"mobipreview.htm?16/28/16834\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In contrast, PIV-2 and PIV-3 occur in annual epidemics in the fall and spring, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/39\">",
"     39",
"    </a>",
"    ]. During years in which PIV-1 is not circulating, there is an increase in PIV-3 activity, manifested either as a longer spring PIV-3 season or as a second smaller peak in the fall. Seasonal patterns of PIV-4 infections have not been established, since the disease is usually mild, and the virus is difficult to detect. However, it is diagnosed more frequently between October and January [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/19\">",
"     19",
"    </a>",
"    ]. In tropical countries, parainfluenza viruses do not exhibit seasonal variation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ethnicity and sex may play roles in the severity of PIV infection. Bronchiolitis occurs most commonly in non-Caucasian males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/25\">",
"     25",
"    </a>",
"    ]. Breast-fed infants have a reduced risk of serious infection. Spread within families is extensive, requiring only direct person-to-person contact or large droplet inhalation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pneumococcal vaccination has been associated with a reduction in the incidence of pneumonia in infants with PIV and other respiratory virus infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/43\">",
"     43",
"    </a>",
"    ]. This observation suggests that the pneumococcus is an important pathogen in virus-associated pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=see_link\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parainfluenza viruses (PIV) cause a variety of upper and lower respiratory tract illnesses, ranging from mild cold-like syndromes to life-threatening pneumonia; they cause a greater proportion of respiratory infections in outpatients than in hospitalized patients.",
"   </p>",
"   <p>",
"    In children, more than 50 percent of PIV infections are upper respiratory infections (URIs), of which 30 to 50 percent are complicated by otitis media [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/36,44\">",
"     36,44",
"    </a>",
"    ]; approximately 15 percent of PIV infections involve the lower respiratory tract. Strong relationships exist between PIV infection and specific clinical syndromes in children.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PIV-1 is the leading cause of croup or laryngotracheobronchitis in children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/1\">",
"       1",
"      </a>",
"      ]. Children initially present with fever, rhinorrhea, and pharyngitis and progress to cough, often \"barking\" in nature, with stridor, dyspnea, and chest wall retractions. Respiratory distress requiring hospitalization can occur and, rarely, hypoxemia from viral involvement in the lung parenchyma is seen. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43529?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical features, evaluation, and diagnosis of croup\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      PIV-2 also is associated with croup, although the illness generally is milder than with PIV-1.",
"     </li>",
"     <li>",
"      PIV-3 is associated with pneumonia and bronchiolitis in the first six months of life, mimicking RSV infection.",
"     </li>",
"     <li>",
"      PIV-4 typically causes only mild URI symptoms in both adults and children. However, PIV-4 has been isolated in cases of bronchiolitis, pneumonia, croup, apnea, and paroxysmal cough in young infants and in children with underlying conditions, such as developmental disabilities, chronic cardiopulmonary disease, or immunosuppression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Otitis media and sinusitis can result from either primary viral infections or secondary bacterial superinfection. Nonrespiratory complications of PIV are rare but include meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/45\">",
"     45",
"    </a>",
"    ], myocarditis and pericarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/46\">",
"     46",
"    </a>",
"    ], and Guillain-Barr&eacute; syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34647?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/265?source=see_link\">",
"     \"Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/21/10586?source=see_link&amp;anchor=H3#H3\">",
"     \"Viral meningitis: Clinical features and diagnosis in children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although most PIV infections are mild, serious complications can occur, particularly in immunocompromised patients. Immunocompromised children and adults can progress from mild URI symptoms to severe pneumonia with prolonged viral shedding and dissemination.",
"   </p>",
"   <p>",
"    In one report, 2.2 percent of 1253 children and adults who underwent bone marrow transplantation developed symptomatic PIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/48\">",
"     48",
"    </a>",
"    ]. These patients are at particular risk of severe PIV-associated pneumonia, with prolonged shedding and mortality rates of up to 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/5,48-54\">",
"     5,48-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of children with hematologic malignancies at a pediatric cancer center, PIV was the second most common respiratory viral infection after influenza, detected in 10 percent of children tested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/55\">",
"     55",
"    </a>",
"    ]. Ninety percent of PIV infections were community acquired. PIV 3 accounted for 61 percent of PIV infections. PIV infections were approximately four times more common in children with acute lymphoblastic leukemia than in those with other hematologic malignancies. Although most (80 percent) of children had upper respiratory tract illness, children who were young (median age 27 months) and presented with fever, severe neutropenia, or lymphopenia were at increased risk for lower respiratory tract infection.",
"   </p>",
"   <p>",
"    Solid organ transplant recipients are at an increased risk for pulmonary complications. Complications such as bronchiolitis obliterans, and acute and chronic rejection have been reported in lung transplant patients with PIV and other respiratory viral infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Children with severe T cell deficiencies can succumb to fatal giant cell pneumonia after infection with PIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of parainfluenza virus (PIV) infection can be made clinically with a compatible presentation during an outbreak of PIV in the community. Laboratory confirmation may be useful in determining if a community outbreak exists or in excluding other infections in seriously ill patients.",
"   </p>",
"   <p>",
"    When diagnosis is necessary, we usually obtain nasopharyngeal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    oropharyngeal specimens for polymerase chain reaction (PCR) given its high sensitivity and rapid turn-around time. If PCR is not available, we suggest rapid antigen detection and culture. We generally do not use serology for the diagnosis of PIV.",
"   </p>",
"   <p>",
"    PCR assays permit the detection of PIV and a number of respiratory viruses in nasopharyngeal and oropharyngeal secretions with reported sensitivities of 95 to 100 percent and excellent specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. Collection of paired oropharyngeal and nasopharyngeal samples may increase the sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. PCR increases the yield of detection of PIV-3 by 1.5-fold, compared with viral culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PIV also can be identified by culture from the nasopharynx (nasopharyngeal swabs, aspirates, or washes). Specimens should be placed in viral transport media and kept at 4&ordm;C because the virus loses infectivity at room temperature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/65\">",
"     65",
"    </a>",
"    ]. Hemadsorption and immunofluorescence typing are routinely used for identification, as observed cytopathic effects can be variable.",
"   </p>",
"   <p>",
"    Rapid antigen detection by immunofluorescence and EIA is available with reported sensitivity varying from 60 to 95 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serologic testing also can be performed but is time-consuming and can be confounded by the presence of heterologous antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no antiviral agents with proven efficacy for PIV infections, which are self-limited in most cases. Glucocorticoids and nebulized epinephrine may be used to treat croup. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/26/31144?source=see_link\">",
"     \"Approach to the management of croup\"",
"    </a>",
"    .) The management of bronchiolitis is supportive. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/19/27962?source=see_link&amp;anchor=H2#H2\">",
"     \"Bronchiolitis in infants and children: Treatment; outcome; and prevention\", section on 'Overview of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/59/12216?source=see_link\">",
"     Ribavirin",
"    </a>",
"    and other agents that have been used to treat PIV in immunocompromised hosts are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/617?source=see_link&amp;anchor=H20#H20\">",
"     \"Parainfluenza viruses in adults\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     VACCINE DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no licensed vaccine for parainfluenza viruses (PIV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/7,67\">",
"     7,67",
"    </a>",
"    ]. However, vaccine candidates are being studied in human populations, and a vaccine for use in infants, young children, and immunocompromised adults may be forthcoming.",
"   </p>",
"   <p>",
"    Natural immunity to PIV is incomplete, and reinfection is common; however, reinfections tend to be milder than initial infection and restricted to the upper respiratory tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/68\">",
"     68",
"    </a>",
"    ]. Antibodies are produced to all viral proteins, although only antibodies to the surface proteins, HN and F, are neutralizing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/6\">",
"     6",
"    </a>",
"    ]. T cell immunity contributes to viral clearance and confers transient resistance to reinfection, albeit short lived [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/13,69\">",
"     13,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaccine development began in the 1960s with the production of an inactivated mixture of PIV-1, -2, and -3. This vaccine produced variable antibody responses and did not protect against challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/7\">",
"     7",
"    </a>",
"    ]. Subunit vaccines containing purified HN and F glycoproteins of PIV were later shown to induce functional antibodies in animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/7\">",
"     7",
"    </a>",
"    ]. Using a different approach, a modified vaccinia recombinant, Ankara (MVA), expressing the HN or F protein of PIV-3 tested in non-human primates showed significant protection of the lower respiratory tract but failed to demonstrate significant upper respiratory tract protection against challenge with PIV-3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/70\">",
"     70",
"    </a>",
"    ]. Several live attenuated intranasal vaccine candidates have been developed using cell culture passage or chemical mutagenesis for viral attenuation and reverse genetics technology.",
"   </p>",
"   <p>",
"    Bovine PIV-3 (BPIV-3), a virus that is antigenically related to human PIV-3 (hPIV-3), has been evaluated in clinical trials as a vaccine candidate to protect against PIV-3 in children and infants. However, seroconversion rates to hPIV-3 have been modest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/67,71,72\">",
"     67,71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A live attenuated, cold-adapted PIV-3 vaccine candidate, hPIV-3-cp45, the cp45 derivative of the JS strain of wild-type human PIV-3, was developed in the 1990s. When administered intranasally, it provided almost complete protection against challenge with wild-type PIV-3 in both the upper and lower respiratory tracts in non-human primates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/7\">",
"     7",
"    </a>",
"    ]. HPIV-3-cp45 was found to be appropriately attenuated and immunogenic in children and infants as young as one month of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. Similarly, this vaccine was found to be safe and immunogenic in a phase 2 trial of healthy seropositive and seronegative infants and children, with two or three doses needed to induce durable immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/76\">",
"     76",
"    </a>",
"    ]. A combined",
"    <span class=\"nowrap\">",
"     hPIV-3-cp45/RSV",
"    </span>",
"    experimental vaccine has been studied in 6- to 18-month-old seronegative children, showing antibody responses similar to the monovalent vaccine components [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reverse genetics technology has allowed the development of a cDNA derived recombinant virus rHPIV3-cp45 that is the focus of current clinical development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/13\">",
"     13",
"    </a>",
"    ]. The advantages of this technology include the ability to rapidly produce the vaccine virus with minimal risk of biologic contamination. Phase 1 and 2 clinical trials have shown that this live, attenuated recombinant rHPIV3-cp45 vaccine is well tolerated and immunogenic in infants 6 to 36 months of age, but a three dose regimen might be necessary to elicit protection in infants younger than 6 months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/13,78,79\">",
"     13,78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To improve immunogenicity, two cDNA-derived chimeric",
"    <span class=\"nowrap\">",
"     bovine/human",
"    </span>",
"    PIV3 virus",
"    <span class=\"nowrap\">",
"     (rB/HPIV3)",
"    </span>",
"    constructs have been created by reverse genetics and tested in adults, and HPIV3 seropositive and seronegative infants and children, with promising results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/80\">",
"     80",
"    </a>",
"    ]. Chimeric",
"    <span class=\"nowrap\">",
"     rB/HPIV3",
"    </span>",
"    viruses modified to express the RSV F or both the F and G proteins are bivalent vaccine candidates currently undergoing testing in children to prevent RSV and PIV3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Through reverse genetics, several PIV-1 and PIV-2 candidate vaccines have been developed and are undergoing testing in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/13,67,82-84\">",
"     13,67,82-84",
"    </a>",
"    ]. Another approach under evaluation is the use of a murine PIV (Sendai virus) as a live attenuated xenotropic vaccine against HPIV1, similar to the use of Bovine PIV3. Phase 1 trials of a nasally administered Sendai virus vaccine are underway in adults and children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36808/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parainfluenza viruses (PIV) are single-stranded, enveloped RNA viruses belonging to the genus paramyxovirus in the Paramyxoviridae family. Four major serotypes of human PIV (PIV-1, 2, 3, 4) have been described. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parainfluenza viruses initially infect epithelial cells of the nose and oropharynx and then spread distally to the large and small airways. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PIV cause a variety of upper and lower respiratory tract illnesses, ranging from mild cold-like syndromes to life-threatening pneumonia. PIV-1 and PIV-2 are associated with croup and PIV-3 with pneumonia and bronchiolitis. PIV-4 typically causes mild upper respiratory infection, but pneumonia and bronchiolitis have been described in infants and in children with underlying conditions. Although most PIV infections are mild, serious complications can occur, particularly in immunocompromised patients. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of PIV infection can be made clinically with a compatible presentation during an outbreak of PIV in the community. Laboratory confirmation may be useful in determining if a community outbreak exists or in excluding other infections in seriously ill patients. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no antiviral agents with proven efficacy for PIV infections. PIV infections are generally self-limited and treated with supportive measures. The management of specific clinical syndromes (eg, croup, bronchiolitis) is discussed separately. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/26/31144?source=see_link\">",
"       \"Approach to the management of croup\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/19/27962?source=see_link\">",
"       \"Bronchiolitis in infants and children: Treatment; outcome; and prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vaccine development is ongoing and the outlook is promising, given the availability of reverse genetics technology. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Vaccine development'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/1\">",
"      Denny FW Jr. The clinical impact of human respiratory virus infections. Am J Respir Crit Care Med 1995; 152:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/2\">",
"      Griffin MR, Walker FJ, Iwane MK, et al. Epidemiology of respiratory infections in young children: insights from the new vaccine surveillance network. Pediatr Infect Dis J 2004; 23:S188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/3\">",
"      Weinberg GA, Hall CB, Iwane MK, et al. Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J Pediatr 2009; 154:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/4\">",
"      Wendt CH, Hertz MI. Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host. Semin Respir Infect 1995; 10:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/5\">",
"      Piralla A, Percivalle E, Di Cesare-Merlone A, et al. Multicluster nosocomial outbreak of parainfluenza virus type 3 infection in a pediatric oncohematology unit: a phylogenetic study. Haematologica 2009; 94:833.",
"     </a>",
"    </li>",
"    <li>",
"     Karron RA, Colling PL. Parainfluenza viruses. In: Fields Virology, Knipe DM, Howley PM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. p.1497.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/7\">",
"      Murphy BR, Hall SL, Kulkarni AB, et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res 1994; 32:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/8\">",
"      Tao T, Durbin AP, Whitehead SS, et al. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1. J Virol 1998; 72:2955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/9\">",
"      Patterson S, Gross J, Oxford JS. The intracellular distribution of influenza virus matrix protein and nucleoprotein in infected cells and their relationship to haemagglutinin in the plasma membrane. J Gen Virol 1988; 69 ( Pt 8):1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/10\">",
"      Hamaguchi M, Yoshida T, Nishikawa K, et al. Transcriptive complex of Newcastle disease virus. I. Both L and P proteins are required to constitute an active complex. Virology 1983; 128:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/11\">",
"      Moscona A. Interaction of human parainfluenza virus type 3 with the host cell surface. Pediatr Infect Dis J 1997; 16:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/12\">",
"      Huberman K, Peluso RW, Moscona A. Hemagglutinin-neuraminidase of human parainfluenza 3: role of the neuraminidase in the viral life cycle. Virology 1995; 214:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/13\">",
"      Bartlett EJ, Cruz AM, Boonyaratanakornkit J, et al. A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates. Vaccine 2010; 28:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/14\">",
"      Boonyaratanakornkit J, Bartlett E, Schomacker H, et al. The C proteins of human parainfluenza virus type 1 limit double-stranded RNA accumulation that would otherwise trigger activation of MDA5 and protein kinase R. J Virol 2011; 85:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/15\">",
"      Zhang L, Collins PL, Lamb RA, Pickles RJ. Comparison of differing cytopathic effects in human airway epithelium of parainfluenza virus 5 (W3A), parainfluenza virus type 3, and respiratory syncytial virus. Virology 2011; 421:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/16\">",
"      Walker TA, Khurana S, Tilden SJ. Viral respiratory infections. Pediatr Clin North Am 1994; 41:1365.",
"     </a>",
"    </li>",
"    <li>",
"     Wright PF. Parainfluenza viruses. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, New York 2005. p.1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/18\">",
"      Rubin EE, Quennec P, McDonald JC. Infections due to parainfluenza virus type 4 in children. Clin Infect Dis 1993; 17:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/19\">",
"      Slavin KA, Passaro DJ, Hacker JK, et al. Parainfluenza virus type 4: case report and review of the literature. Pediatr Infect Dis J 2000; 19:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/20\">",
"      Lau SK, To WK, Tse PW, et al. Human parainfluenza virus 4 outbreak and the role of diagnostic tests. J Clin Microbiol 2005; 43:4515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/21\">",
"      Castleman WL, Brundage-Anguish LJ, Kreitzer L, Neuenschwander SB. Pathogenesis of bronchiolitis and pneumonia induced in neonatal and weanling rats by parainfluenza (Sendai) virus. Am J Pathol 1987; 129:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/22\">",
"      Zhang L, Bukreyev A, Thompson CI, et al. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol 2005; 79:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/23\">",
"      Porter DD, Prince GA, Hemming VG, Porter HG. Pathogenesis of human parainfluenza virus 3 infection in two species of cotton rats: Sigmodon hispidus develops bronchiolitis, while Sigmodon fulviventer develops interstitial pneumonia. J Virol 1991; 65:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/24\">",
"      Prince GA, Porter DD. Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid. J Infect Dis 1996; 173:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/25\">",
"      Welliver RC, Wong DT, Sun M, McCarthy N. Parainfluenza virus bronchiolitis. Epidemiology and pathogenesis. Am J Dis Child 1986; 140:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/26\">",
"      Wilson J, Rowlands K, Rockett K, et al. Genetic variation at the IL10 gene locus is associated with severity of respiratory syncytial virus bronchiolitis. J Infect Dis 2005; 191:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/27\">",
"      Crowe JE Jr, Williams JV. Immunology of viral respiratory tract infection in infancy. Paediatr Respir Rev 2003; 4:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/28\">",
"      Schaap-Nutt A, Scull MA, Schmidt AC, et al. Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys. Vaccine 2010; 28:2788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/29\">",
"      Schmidt AC, Schaap-Nutt A, Bartlett EJ, et al. Progress in the development of human parainfluenza virus vaccines. Expert Rev Respir Med 2011; 5:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/30\">",
"      Welliver RC, Wong DT, Middleton E Jr, et al. Role of parainfluenza virus-specific IgE in pathogenesis of croup and wheezing subsequent to infection. J Pediatr 1982; 101:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/31\">",
"      Einarsson O, Geba GP, Zhu Z, et al. Interleukin-11: stimulation in vivo and in vitro by respiratory viruses and induction of airways hyperresponsiveness. J Clin Invest 1996; 97:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/32\">",
"      Jacoby DB, Xiao HQ, Lee NH, et al. Virus- and interferon-induced loss of inhibitory M2 muscarinic receptor function and gene expression in cultured airway parasympathetic neurons. J Clin Invest 1998; 102:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/33\">",
"      Ottolini MG, Hemming VG, Piazza FM, et al. Topical immunoglobulin is an effective therapy for parainfluenza type 3 in a cotton rat model. J Infect Dis 1995; 172:243.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Parainfluenza viral infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/35\">",
"      PARROTT RH, VARGOSKO AJ, BELL JA, et al. Acute respiratory diseases of viral etiology. III. parainfluenza. Myxoviruses. Am J Public Health Nations Health 1962; 52:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/36\">",
"      Reed G, Jewett PH, Thompson J, et al. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children &lt; 5 years old. J Infect Dis 1997; 175:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/37\">",
"      Hemming VG. Viral respiratory diseases in children: classification, etiology, epidemiology, and risk factors. J Pediatr 1994; 124:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/38\">",
"      Counihan ME, Shay DK, Holman RC, et al. Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States. Pediatr Infect Dis J 2001; 20:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/39\">",
"      Fry AM, Curns AT, Harbour K, et al. Seasonal trends of human parainfluenza viral infections: United States, 1990-2004. Clin Infect Dis 2006; 43:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/40\">",
"      Marx A, T&ouml;r&ouml;k TJ, Holman RC, et al. Pediatric hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1 epidemics. J Infect Dis 1997; 176:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/41\">",
"      Chew FT, Doraisingham S, Ling AE, et al. Seasonal trends of viral respiratory tract infections in the tropics. Epidemiol Infect 1998; 121:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/42\">",
"      Ansari SA, Springthorpe VS, Sattar SA, et al. Potential role of hands in the spread of respiratory viral infections: studies with human parainfluenza virus 3 and rhinovirus 14. J Clin Microbiol 1991; 29:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/43\">",
"      Madhi SA, Klugman KP, Vaccine Trialist Group. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004; 10:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/44\">",
"      Vesa S, Kleemola M, Blomqvist S, et al. Epidemiology of documented viral respiratory infections and acute otitis media in a cohort of children followed from two to twenty-four months of age. Pediatr Infect Dis J 2001; 20:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/45\">",
"      Arisoy ES, Demmler GJ, Thakar S, Doerr C. Meningitis due to parainfluenza virus type 3: report of two cases and review. Clin Infect Dis 1993; 17:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/46\">",
"      Wilks D, Burns SM. Myopericarditis associated with parainfluenza virus type 3 infection. Eur J Clin Microbiol Infect Dis 1998; 17:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/47\">",
"      Rom&aacute;n G, Phillips CA, Poser CM. Parainfluenza virus type 3: isolation from CSF of a patient with Guillain-Barr&eacute; syndrome. JAMA 1978; 240:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/48\">",
"      Wendt CH, Weisdorf DJ, Jordan MC, et al. Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med 1992; 326:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/49\">",
"      Taylor CE, Osman HK, Turner AJ, et al. Parainfluenza virus and respiratory syncytial virus infection in infants undergoing bone marrow transplantation for severe combined immunodeficiency. Commun Dis Public Health 1998; 1:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/50\">",
"      Zambon M, Bull T, Sadler CJ, et al. Molecular epidemiology of two consecutive outbreaks of parainfluenza 3 in a bone marrow transplant unit. J Clin Microbiol 1998; 36:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/51\">",
"      Elizaga J, Olavarria E, Apperley J, et al. Parainfluenza virus 3 infection after stem cell transplant: relevance to outcome of rapid diagnosis and ribavirin treatment. Clin Infect Dis 2001; 32:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/52\">",
"      Maziarz RT, Sridharan P, Slater S, et al. Control of an outbreak of human parainfluenza virus 3 in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2010; 16:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/53\">",
"      Nichols WG, Erdman DD, Han A, et al. Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis. Biol Blood Marrow Transplant 2004; 10:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/54\">",
"      Campbell AP, Chien JW, Kuypers J, et al. Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT. J Infect Dis 2010; 201:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/55\">",
"      Srinivasan A, Wang C, Yang J, et al. Parainfluenza virus infections in children with hematologic malignancies. Pediatr Infect Dis J 2011; 30:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/56\">",
"      Vu DL, Bridevaux PO, Aubert JD, et al. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant 2011; 11:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/57\">",
"      Kumar D, Husain S, Chen MH, et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 2010; 89:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/58\">",
"      Osiowy C. Direct detection of respiratory syncytial virus, parainfluenza virus, and adenovirus in clinical respiratory specimens by a multiplex reverse transcription-PCR assay. J Clin Microbiol 1998; 36:3149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/59\">",
"      Fan J, Henrickson KJ, Savatski LL. Rapid simultaneous diagnosis of infections with respiratory syncytial viruses A and B, influenza viruses A and B, and human parainfluenza virus types 1, 2, and 3 by multiplex quantitative reverse transcription-polymerase chain reaction-enzyme hybridization assay (Hexaplex). Clin Infect Dis 1998; 26:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/60\">",
"      Puppe W, Weigl JA, Aron G, et al. Evaluation of a multiplex reverse transcriptase PCR ELISA for the detection of nine respiratory tract pathogens. J Clin Virol 2004; 30:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/61\">",
"      Selvaraju SB, Selvarangan R. Evaluation of xTAG Respiratory Viral Panel FAST and xTAG Human Parainfluenza Virus Analyte-Specific Reagents for detection of human parainfluenza viruses in respiratory specimens. Diagn Microbiol Infect Dis 2012; 72:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/62\">",
"      Kim C, Ahmed JA, Eidex RB, et al. Comparison of nasopharyngeal and oropharyngeal swabs for the diagnosis of eight respiratory viruses by real-time reverse transcription-PCR assays. PLoS One 2011; 6:e21610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/63\">",
"      Hammitt LL, Kazungu S, Welch S, et al. Added value of an oropharyngeal swab in detection of viruses in children hospitalized with lower respiratory tract infection. J Clin Microbiol 2011; 49:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/64\">",
"      Weinberg GA, Erdman DD, Edwards KM, et al. Superiority of reverse-transcription polymerase chain reaction to conventional viral culture in the diagnosis of acute respiratory tract infections in children. J Infect Dis 2004; 189:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/65\">",
"      Frank AL, Couch RB, Griffis CA, Baxter BD. Comparison of different tissue cultures for isolation and quantitation of influenza and parainfluenza viruses. J Clin Microbiol 1979; 10:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/66\">",
"      Ray CG, Minnich LL. Efficiency of immunofluorescence for rapid detection of common respiratory viruses. J Clin Microbiol 1987; 25:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/67\">",
"      Schmidt AC. Progress in respiratory virus vaccine development. Semin Respir Crit Care Med 2007; 28:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/68\">",
"      Glezen WP, Frank AL, Taber LH, Kasel JA. Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children. J Infect Dis 1984; 150:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/69\">",
"      Takamura S, Roberts AD, Jelley-Gibbs DM, et al. The route of priming influences the ability of respiratory virus-specific memory CD8+ T cells to be activated by residual antigen. J Exp Med 2010; 207:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/70\">",
"      Durbin AP, Wyatt LS, Siew J, et al. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys. Vaccine 1998; 16:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/71\">",
"      Lee MS, Greenberg DP, Yeh SH, et al. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants. J Infect Dis 2001; 184:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/72\">",
"      Greenberg DP, Walker RE, Lee MS, et al. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. J Infect Dis 2005; 191:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/73\">",
"      Karron RA, Wright PF, Hall SL, et al. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis 1995; 171:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/74\">",
"      Karron RA, Makhene M, Gay K, et al. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants. Pediatr Infect Dis J 1996; 15:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/75\">",
"      Karron RA, Belshe RB, Wright PF, et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J 2003; 22:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/76\">",
"      Belshe RB, Newman FK, Tsai TF, et al. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old. J Infect Dis 2004; 189:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/77\">",
"      Belshe RB, Newman FK, Anderson EL, et al. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. J Infect Dis 2004; 190:2096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/78\">",
"      Bernstein DI, Falloon J, Yi T. A randomized, double-blind, placebo-controlled, phase 1/2a study of the safety and immunogenicity of a live, attenuated human parainfluenza virus type 3 vaccine in healthy infants. Vaccine 2011; 29:7042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/79\">",
"      Bernstein DI, Malkin E, Abughali N, et al. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J 2012; 31:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/80\">",
"      Karron RA, Thumar B, Schappell E, et al. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children. Vaccine 2011.",
"     </a>",
"    </li>",
"    <li>",
"     Bernstein D, Malkin E, Charenkavanich S, Dubovsky F. Safety profile, immunogenicity and viral shedding of MEDI-534, a live, attenuated respiratory syncytial virus (RSV) and parainfluenza virus 3 (PIV3) vaccine in RSV/PIV3 seronegative children. Presented at: International RSV symposium. GCO BV, Rotterdam, The Netherlands, December 2-5, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/82\">",
"      Bartlett EJ, Amaro-Carambot E, Surman SR, et al. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys. Vaccine 2005; 23:4631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/83\">",
"      Nolan SM, Surman SR, Amaro-Carambot E, et al. Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses. Vaccine 2005; 23:4765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/84\">",
"      Bartlett EJ, Casta&ntilde;o A, Surman SR, et al. Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes. Virol J 2007; 4:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36808/abstract/85\">",
"      Slobod KS, Shenep JL, Luj&aacute;n-Zilbermann J, et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 2004; 22:3182.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5975 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-B6001DE224-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_60_36808=[""].join("\n");
var outline_f35_60_36808=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Viral serotypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Incubation period",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      VACCINE DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5975\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5975|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/28/16834\" title=\"figure 1\">",
"      PIV seasonality",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/26/31144?source=related_link\">",
"      Approach to the management of croup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/19/27962?source=related_link\">",
"      Bronchiolitis in infants and children: Treatment; outcome; and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43529?source=related_link\">",
"      Clinical features, evaluation, and diagnosis of croup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34647?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/617?source=related_link\">",
"      Parainfluenza viruses in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/265?source=related_link\">",
"      Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/21/10586?source=related_link\">",
"      Viral meningitis: Clinical features and diagnosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_60_36809="Forearm volar anatomy";
var content_f35_60_36809=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bones, muscles, and compartments of forearm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 767px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) In this image, the superficial muscles of the forearm and the palmar aponeurosis are revealed.",
"    <br>",
"     (B) Here, the flexor digitorum superficialis (FDS) and related structures are shown. Observe the ulnar artery descending obliquely posterior to the FDS to meet and accompany the ulnar nerve.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"     </div>",
"     <div class=\"contractual\">",
"      <br/>",
"      <a href=\"file://www.lww.com\">",
"       file://www.lww.com",
"      </a>",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_60_36809=[""].join("\n");
var outline_f35_60_36809=null;
var title_f35_60_36810="Estimation of cardiac risk prior to noncardiac surgery";
var content_f35_60_36810=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Estimation of cardiac risk prior to noncardiac surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/60/36810/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/60/36810/contributors\">",
"     Jonathan B Shammash, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/60/36810/contributors\">",
"     Stephen E Kimmel, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/60/36810/contributors\">",
"     James P Morgan, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/60/36810/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/60/36810/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/60/36810/contributors\">",
"     Patricia A Pellikka, MD, FACC, FAHA, FASE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/60/36810/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/60/36810/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/60/36810/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular complications pose one of the most significant risks to patients undergoing major noncardiac surgery. A prospective study published in 1977 evaluated 1001 such patients who were over age 40; the overall risk of postoperative cardiac death or major cardiac complications (including nonfatal myocardial infarction [MI], pulmonary edema, or ventricular tachycardia) was 5.8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 1995 review of major published series found that the pooled average rates of the more selective outcome of MI and cardiac death varied with the population studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among unselected patients over age 40 &mdash; MI in 1.4 percent and cardiac death in 1.0 percent.",
"     </li>",
"     <li>",
"      Among consecutive surgical patients with some selection criteria &mdash; MI in 3.2 percent and cardiac death in 1.7 percent.",
"     </li>",
"     <li>",
"      Among patients selected to undergo preoperative thallium scintigraphy &mdash; MI in 6.9 percent and cardiac death in 3.2 percent. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Dipyridamole rMPI'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with underlying cardiovascular disease (eg, peripheral artery disease, stroke) have an increased risk of perioperative cardiac complications for two reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They constitute a selected population with a high incidence of significant coronary artery disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. In addition, left ventricular systolic dysfunction (left ventricular ejection fraction &le;40 percent) is five times more common in patients with cerebrovascular disease or peripheral artery disease compared with matched controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Physiologic factors associated with surgery predisposed to myocardial ischemia, which is more pronounced in patients with underlying coronary disease. These include volume shifts and blood loss, enhanced myocardial oxygen demand from elevations in heart rate and blood pressure secondary to stress from surgery, and an increase in postoperative platelet reactivity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal approach is to identify patients at high risk so that appropriate testing and therapeutic measures can be undertaken to minimize this risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/7\">",
"     7",
"    </a>",
"    ]. The range of risk was illustrated in a retrospective study of 663,665 adults with no contraindications to beta blockers who underwent major noncardiac surgery in 2000 and 2001 at 329 hospitals in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/8\">",
"     8",
"    </a>",
"    ]. Orthopedic and abdominal surgery accounted for 70 percent of cases. In-hospital mortality in patients not treated with beta blockers increased progressively from 1.4 to 7.4 percent according to a preoperative assessment of risk using the revised cardiac risk index described below. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Revised cardiac risk index'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This topic will review the initial preoperative evaluation, the surgery-specific risk, and the major indices used for risk stratification in patients undergoing noncardiac surgery. The management of cardiac risk in an attempt to reduce morbidity and mortality and issues related to the perioperative evaluation and management of heart failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link\">",
"     \"Management of cardiac risk for noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18440?source=see_link\">",
"     \"Perioperative heart failure in noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician must integrate information from the history, physical examination, and electrocardiogram in order to develop an initial estimate of perioperative cardiac risk. The 2007 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on perioperative cardiovascular evaluation for noncardiac surgery (not changed in the 2009 focused update) concluded that three elements must be assessed to determine the risk of cardiac events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patient specific clinical variables (",
"      <a class=\"graphic graphic_table graphicRef62292 \" href=\"mobipreview.htm?26/56/27532\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Exercise capacity",
"     </li>",
"     <li>",
"      Surgery-specific risk (",
"      <a class=\"graphic graphic_table graphicRef57828 \" href=\"mobipreview.htm?7/2/7212\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed history of the patient's symptoms, clinical course, and exercise tolerance yields valuable information for risk assessment. In particular, the initial preoperative evaluation should include a history inquiring about previous coronary heart disease, symptoms of angina, heart failure (HF), aortic stenosis, severe hypertension, and peripheral artery disease (PAD). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical predictors of perioperative risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Functional capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;An assessment of cardiac functional status should also be performed. The assessment of functional ability provides valuable prognostic information, since patients with good functional status have a lower risk of complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/2\">",
"     2",
"    </a>",
"    ]. Functional status can be expressed in metabolic equivalents (1 MET is defined as 3.5 mL O2",
"    <span class=\"nowrap\">",
"     uptake/kg",
"    </span>",
"    per min, which is the resting oxygen uptake in a sitting position). Perioperative cardiac and long-term risk is increased in patients unable to meet a 4-MET demand during most normal daily activities.",
"   </p>",
"   <p>",
"    Various activity scales provide the clinician with a set of questions to determine a patient's functional capacity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/10\">",
"     10",
"    </a>",
"    ]. Indicators of functional status include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Can take care of self, such as eat, dress or use the toilet (1 MET)",
"     </li>",
"     <li>",
"      Can walk up a flight of steps or a hill (4 METs)",
"     </li>",
"     <li>",
"      Can do heavy work around the house such as scrubbing floors or lifting or moving heavy furniture (between 4 and 10 METs)",
"     </li>",
"     <li>",
"      Can participate in strenuous sports such as swimming, singles tennis, football, basketball, and skiing (&gt;10 METs)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One important indicator of poor functional status and an increased risk of postoperative cardiopulmonary complications after major noncardiac surgery is the inability to climb two flights of stairs or walk four blocks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. However, the presence of peripheral artery disease may be an important limitation to assessment of functional capacity since such patients often cannot exercise because of claudication.",
"   </p>",
"   <p>",
"    The triad of good functional status, the absence of known cardiovascular disease, and a low score on one of the multifactorial risk indices described below is associated with a very low rate of major complications, even in patients undergoing major vascular surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of cardiopulmonary exercise testing to determine functional capacity in this setting is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should include blood pressure measurements in both arms, an analysis of carotid artery and jugular venous pulsations for the quality of the pulse contour and the presence of bruits, auscultation of the lungs, precordial palpation and auscultation, abdominal palpation, and examination of the extremities for edema and vascular integrity. Important findings include evidence of HF or a murmur suspicious for aortic stenosis (AS), since poorly controlled HF and significant AS increase perioperative risk. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical predictors of perioperative risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Resting electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of Q waves or significant ST segment elevation or depression have been associated with an increased incidence of perioperative cardiac complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The additional value of the preoperative ECG compared to clinical characteristics was evaluated in a retrospective study of 2422 noncardiac surgery patients (54 percent referred for high risk surgery) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/15\">",
"     15",
"    </a>",
"    ]. Although right or left bundle branch block was associated with perioperative MI and left bundle branch block was associated with perioperative mortality, no single ECG abnormality provided additional predictive value for perioperative myocardial infarction or death in multivariate analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Guideline recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on perioperative cardiovascular evaluation (not changed in the 2009 focused update) recommended a preoperative resting 12-lead ECG in patients with at least one clinical risk factor scheduled to undergo vascular surgery (",
"    <a class=\"graphic graphic_table graphicRef62292 \" href=\"mobipreview.htm?26/56/27532\">",
"     table 1",
"    </a>",
"    ) OR those patients scheduled to undergo intermediate-risk surgery with known cardiovascular disease, peripheral artery disease or cerebrovascular disease (",
"    <a class=\"graphic graphic_table graphicRef53530 \" href=\"mobipreview.htm?19/6/19564\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/9\">",
"     9",
"    </a>",
"    ]. A less strong recommendation was given for those scheduled to undergo vascular surgery with no clinical risk factors OR those scheduled to undergo intermediate-risk surgery with at least one clinical risk factor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL PREDICTORS OF PERIOPERATIVE RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines (not changed in the 2009 focused update) summarized clinical predictors of increased perioperative risk for myocardial infarction, HF, and cardiac death (",
"    <a class=\"graphic graphic_table graphicRef62292 \" href=\"mobipreview.htm?26/56/27532\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/9\">",
"     9",
"    </a>",
"    ]. These predictors, which are derived from the history, physical examination, and resting ECG, help the clinician decide which patients may benefit most from further evaluation and aggressive management (medical or coronary revascularization).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Major predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a major risk factor as described below is present, intensive management is mandated, which may result in delay or cancellation of surgery unless it is emergent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Recent MI or severe angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two unstable coronary syndromes which are associated with a major perioperative risk: recent myocardial infarction (MI), and unstable or severe angina.",
"   </p>",
"   <p>",
"    The definition of recent MI has been modified with significant clinical implications. In the past, patients post-MI have been considered as being either three or six months status post-MI, and perioperative cardiac complication rates were assessed for these intervals. Older studies found as much as a 36 percent risk of reinfarction or cardiac death when patients underwent surgery within three months of a previous MI; the risk fell to 15 to 25 percent at three to six months; and 5 percent when surgery was performed after more than six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the risk was lower in later studies in the era of preoperative optimization and intensive perioperative monitoring. As an example, a prospective study performed between 1977 and 1982 evaluated the incidence of recurrent perioperative MI in 733 patients who had had a previous MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/16\">",
"     16",
"    </a>",
"    ]. The reinfarction rate was 1.9 percent overall, 2.3 percent for those operated upon three to six months after a previous MI, and 5.7 percent for those operated on within three months of the previous MI. Current acute reperfusion therapies and coronary revascularization after MI presumably reduce the risk further, but data are insufficient.",
"   </p>",
"   <p>",
"    Current management of MI or unstable angina provides for risk-stratification during convalescence in patients who have not been fully revascularized. If a stress test does not indicate ischemic myocardium at risk, the likelihood of reinfarction after noncardiac surgery is low. A positive stress test is usually an indication for revascularization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/43/2746?source=see_link&amp;anchor=H16#H16\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\", section on 'Stress testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/52/35658?source=see_link&amp;anchor=H35#H35\">",
"     \"Risk stratification for cardiac events after acute ST elevation myocardial infarction\", section on 'Stress testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American College of Cardiology National Database Library defines recent MI as greater than seven days but &le;30 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/10\">",
"     10",
"    </a>",
"    ]. Although there are no adequate clinical trials on which to base firm recommendations, it appears reasonable to wait at least four to six weeks after MI to perform elective surgery in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Recent PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining the optimal timing for elective surgery is more difficult in patients who have undergone a recent percutaneous coronary intervention (PCI), particularly with a drug-eluting stent. The risk of both postoperative MI and death is substantially elevated in patients treated with a stent who subsequently discontinue antiplatelet therapy at the time of surgery. For patients treated with a bare metal stent, it may be safe to stop antiplatelet therapy four to six weeks after implantation, but for those treated with a drug-eluting stent, where coronary endothelialization is delayed, it is recommended that dual antiplatelet therapy is continued for at least three to six months and preferably longer, even if surgery is performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link&amp;anchor=H9#H9\">",
"     \"Management of cardiac risk for noncardiac surgery\", section on 'Preoperative PCI'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=see_link&amp;anchor=H11#H11\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Early noncardiac surgery or gastrointestinal endoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Severe angina (Canadian Cardiovascular Society [CCS]) class III or IV; (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 4",
"    </a>",
"    ) is also associated with a major risk of perioperative complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H166915859\">",
"    <span class=\"h3\">",
"     Decompensated heart failure or significant valvular heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decompensated (preoperative) HF or severe valvular disease predicts an increase in risk of mortality at the time of noncardiac surgery. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18440?source=see_link&amp;anchor=H3#H3\">",
"     \"Perioperative heart failure in noncardiac surgery\", section on 'HF as a risk factor for postoperative cardiac complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/14/13544?source=see_link\">",
"     \"Noncardiac surgery in patients with aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Significant arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant arrhythmias are defined as high-grade atrioventricular block, sustained ventricular tachycardia, nonsustained ventricular tachycardia in the presence of underlying heart disease, and supraventricular arrhythmias with an uncontrolled ventricular rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other clinical predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines (not changed in the 2009 focused update) chose to replace intermediate predictors with clinical risk factors in the revised cardiac risk index (",
"    <a class=\"graphic graphic_table graphicRef62292 \" href=\"mobipreview.htm?26/56/27532\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57075 \" href=\"mobipreview.htm?42/4/43083\">",
"     table 5",
"    </a>",
"    ). When present, they justify careful assessment of the patient's current status, which may necessitate noninvasive testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ischemic heart disease including mild angina pectoris (CCS class I or II) (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"       table 4",
"      </a>",
"      ) or prior MI by history or pathologic Q wave",
"     </li>",
"     <li>",
"      Compensated or prior heart failure (HF)",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Renal insufficiency (preoperative creatinine &gt;2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [177",
"      <span class=\"nowrap\">",
"       &micro;mol/L])",
"      </span>",
"     </li>",
"     <li>",
"      Cerebrovascular disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While not included in the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    list of clinical risk factors, a&nbsp;single, retrospective, administrative database study (Alberta, Canada) demonstrated an association between a history of prior admission for atrial fibrillation (AF) and postoperative complications, as well as confirming that compensated or prior HF is a risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/18\">",
"     18",
"    </a>",
"    ]. This study, which included patients undergoing both major and minor surgery, was used to assess the risk of postoperative mortality in patients with stable coronary artery disease (n=13,783), ischemic HF (n=12,249), nonischemic HF (n=7700) or AF (n=4312) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients were assigned a diagnosis of CAD, HF, or AF only if previously hospitalized for that diagnosis. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The unadjusted 30-day mortality was 2.9, 9.2, 9.3, and 6.4 percent respectively in the four groups.",
"     </li>",
"     <li>",
"      After multivariable adjustment, the rates for both HF groups and the AF group were significantly higher than the rate for the CAD group.",
"     </li>",
"     <li>",
"      Patients with HF had a significantly worse outcome than those with CAD even after a minor surgical procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Obese patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of coronary heart disease (CHD) and its risk factors is increased in obese patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/35/3641?source=see_link&amp;anchor=H4#H4\">",
"     \"Obesity, weight reduction, and cardiovascular disease\", section on 'Coronary disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2009 American Heart Association (AHA) scientific advisory on obesity noted an association with cardiac and pulmonary diseases, which may negatively affect the outcome of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heart failure and myocardial steatosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link&amp;anchor=H14#H14\">",
"       \"Health hazards associated with obesity in adults\", section on 'Heart disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sleep apnea with or without pulmonary hypertension, deep vein thrombosis, and pulmonary embolism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=see_link\">",
"       \"Overview of obstructive sleep apnea in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=see_link\">",
"       \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7320?source=see_link\">",
"       \"Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For these reasons obese patients are at increased risk for adverse cardiovascular events at the time of non-cardiac surgery. The estimation of risk is more difficult in obese patients due to the uncertain significance of certain components of the history (dyspnea) and physical examination (lower-extremity edema). The generally poor exercise capacity of the obese further complicates risk assessment.",
"   </p>",
"   <p>",
"    The issue of whether the preoperative approach to obese patients should differ from that in the general population is uncertain. The 2009 scientific advisory on Cardiovascular evaluation and management of severely obese patients undergoing surgery from the AHA states that specific tests should be performed only if the results will change management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/19\">",
"     19",
"    </a>",
"    ]. We agree with that approach and with the following specific suggestions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 12 lead electrocardiogram (ECG) is reasonable in all obese patients with at least one risk factor for CHD (diabetes, smoking, hypertension, or hyperlipidemia) or poor exercise tolerance.",
"     </li>",
"     <li>",
"      A chest radiograph (posteroanterior and lateral) should be obtained on all severely obese patients prior to surgery, as the sensitivity and specificity (for the diagnosis of cardiopulmonary disease) of the physical examination is decreased.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Minor predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor risk factors are recognized markers for cardiovascular disease that have not been definitively proven to independently increase perioperative risk and were not included in the recommendations for treatment by the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    perioperative guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Advanced age (greater than 70 years of age)",
"     </li>",
"     <li>",
"      Abnormal ECG (left ventricular hypertrophy, left bundle branch block, ST-T wave abnormalities)",
"     </li>",
"     <li>",
"      Rhythm other than sinus (such as atrial fibrillation)",
"     </li>",
"     <li>",
"      Uncontrolled systolic hypertension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of more than one of these may lead to a higher suspicion of coronary artery disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SURGERY-SPECIFIC RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type and timing of surgery significantly affects the patient's risk of perioperative cardiac complications. The 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines (not changed in the 2009 focused update) stratified surgical risk by procedure (",
"    <a class=\"graphic graphic_table graphicRef57828 \" href=\"mobipreview.htm?7/2/7212\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/9\">",
"     9",
"    </a>",
"    ]. By definition, the reported rate of cardiac death or nonfatal MI is more than 5 percent in high-risk procedures, between 1 and 5 percent in intermediate-risk procedures, and less than 1 percent in low-risk procedures. Institutional",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    individual surgeon experience with the procedure may increase or lower the risk. Emergency surgery is associated with particularly high risk, as cardiac complications are two to five times more likely than with elective procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114518093\">",
"    <span class=\"h2\">",
"     Invasive dental procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic periodontitis has been associated with an increased risk of coronary heart disease events in observational studies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16873?source=see_link&amp;anchor=H21#H21\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections\", section on 'Association with cardiovascular risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although invasive dental procedures are associated with bacteremia and are often performed in patients with chronic periodontitis, dental procedures are considered to be of low cardiovascular risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/21\">",
"     21",
"    </a>",
"    ] and were not mentioned in the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines (",
"    <a class=\"graphic graphic_table graphicRef57828 \" href=\"mobipreview.htm?7/2/7212\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/9\">",
"     9",
"    </a>",
"    ]. The relationship between cardiovascular risk and invasive dental procedures (defined as those that could possibly result in bacteremia and induce an inflammatory response) was evaluated in a self-controlled case series in 1152 individuals who sustained either an ischemic stroke or myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/22\">",
"     22",
"    </a>",
"    ]. The rate of vascular events significantly increased in the first four weeks after invasive dental treatment (incidence ratio 1.50, 95% CI 1.09-2.06, reflecting an increase in absolute risk of approximately 1.2 percent) and gradually returned to the baseline rate within six months. The observational nature of this study precludes drawing definitive conclusions about the observed relationship.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     RISK MODELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multivariable analyses, initially developed by Goldman, Detsky, and Eagle, identified combinations of factors, generally based upon routine clinical information and laboratory tests, that could be used to estimate the risk of cardiac complications. These risk indices were derived from patients who were candidates for surgery; they did not include patients with high-risk conditions that were considered major predictors of risk in the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines that require intensive management and often lead to delay in or cancellation of surgery (",
"    <a class=\"graphic graphic_table graphicRef62292 \" href=\"mobipreview.htm?26/56/27532\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Major predictors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    More recent models such as the Revised cardiac risk index and the National Surgical Quality Improvement Program (NSQIP)risk model, have included patients with high risk characteristics and who have been managed with more current standards of care. For these reasons, we suggest using one of these two models.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Goldman risk index",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1977, Goldman and colleagues assigned a point value to each of nine clinical risk factors and divided 1001 surgical patients into four risk classes on the basis of their total point scores (",
"    <a class=\"graphic graphic_table graphicRef64824 \" href=\"mobipreview.htm?29/62/30700\">",
"     table 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/1\">",
"     1",
"    </a>",
"    ]. Due to multiple limitations, including complexity and changes in the perioperative care of patient, we do not recommend the use of this model.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Revised cardiac risk index",
"    </span>",
"    &nbsp;&mdash;&nbsp;To simplify the prediction of risk, Goldman monitored 2893 patients (mean age 66) undergoing elective major noncardiac procedures and identified six independent predictors of major cardiac complications (defined as myocardial infarction, pulmonary edema, ventricular fibrillation or primary cardiac arrest, and complete heart block; all cause mortality was not included) (",
"    <a class=\"graphic graphic_table graphicRef57075 \" href=\"mobipreview.htm?42/4/43083\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-risk type of surgery (intraperitoneal, intrathoracic, or suprainguinal vascular surgery)",
"     </li>",
"     <li>",
"      History of ischemic heart disease (history of MI or a positive exercise test, current complaint of chest pain considered to be secondary to myocardial ischemia, use of nitrate therapy, or ECG with pathological Q waves; do not count prior coronary revascularization procedure unless one of the other criteria for ischemic heart disease is present)",
"     </li>",
"     <li>",
"      History of HF",
"     </li>",
"     <li>",
"      History of cerebrovascular disease",
"     </li>",
"     <li>",
"      Diabetes mellitus requiring treatment with insulin",
"     </li>",
"     <li>",
"      Preoperative serum creatinine &gt;2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (177",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These predictors were then validated in a cohort of 1422 patients. The predictive value was significant in all types of elective major noncardiac surgery except for abdominal aortic aneurysm surgery (",
"    <a class=\"graphic graphic_figure graphicRef68956 \" href=\"mobipreview.htm?9/11/9406\">",
"     figure 1",
"    </a>",
"    ). A 2009 systematic review evaluated the ability of the revised cardiac risk index (RCRI) to predict cardiac complications and mortality after major non-cardiac surgery in various populations and settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/23\">",
"     23",
"    </a>",
"    ]. The RCRI performed moderately well in distinguishing patients at low compared to high risk for all types of non-cardiac surgery, but was somewhat less accurate in patients undergoing only vascular non-cardiac surgery. In addition, RCRI did not predict all-cause mortality well, but this is expected, as it does not capture risk factors for noncardiac causes of perioperative mortality. Only one third of perioperative deaths are due to cardiac causes.",
"   </p>",
"   <p>",
"    The risk of major cardiac complications varied according to the number of risk factors. If one includes only cardiac death, nonfatal MI, and nonfatal cardiac arrest as major cardiac events in the Goldman cohort, the following rates of adverse outcomes were seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No risk factors &mdash; 0.4 percent (95% CI 0.1-0.8 percent)",
"     </li>",
"     <li>",
"      One risk factor &mdash; 1.0 percent (95% CI 0.5-1.4 percent)",
"     </li>",
"     <li>",
"      Two risk factors &mdash; 2.4 percent (95% CI 1.3-3.5 percent)",
"     </li>",
"     <li>",
"      Three or more risk factors &mdash; 5.4 percent (95% CI 2.8-7.9 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The RCRI has better predictive value than the original Goldman index or the Detsky modified risk index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Later studies have found a higher rate of events at the same RCRI as in the Goldman cohort in which the patients were seen between 1989 and 1994:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large retrospective analysis on mortality, the perioperative risk was evaluated in 663,665 adults with no contraindications to beta blockers who underwent major noncardiac surgery in 2000 and 2001 at 329 hospitals in the United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/8\">",
"       8",
"      </a>",
"      ]. In-hospital mortality in patients not treated with beta blockers increased progressively from 1.4 percent at a score of 0, to 7.4 percent at a score &ge;4. The rate of mortality in this study was higher at the same RCRI than the combined end point of cardiac death, nonfatal MI, and nonfatal cardiac arrest in the earlier Goldman population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the POISE randomized trial of over 8000 patients undergoing noncardiac surgery between 2002 and 2007, the combined rate of cardiovascular death, nonfatal MI, and nonfatal cardiac arrest was 6.9 percent in the placebo group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/24\">",
"       24",
"      </a>",
"      ]. The majority of these individuals were RCRI 1 or 2. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link&amp;anchor=H44#H44\">",
"       \"Management of cardiac risk for noncardiac surgery\", section on 'Beta blockers'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are at least four factors that probably contribute to the higher event rate in these two later studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients were sicker at baseline in the later studies, an effect that may be even larger now.",
"     </li>",
"     <li>",
"      The original RCRI risk prediction model did not take mortality into account [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In earlier studies CK-MB was used to diagnose MI, rather than troponins, which are more sensitive.",
"     </li>",
"     <li>",
"      The original RCRI study did not include patients requiring emergent surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Perioperative myocardial infarction after noncardiac surgery is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29975?source=see_link\">",
"     \"Perioperative myocardial infarction after noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3260416\">",
"    <span class=\"h2\">",
"     NSQIP database risk model",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Surgeons&rsquo; National Surgical Quality Improvement Program database was used to determine risk factors associated with",
"    <span class=\"nowrap\">",
"     intraoperative/postoperative",
"    </span>",
"    myocardial infarction or cardiac arrest (MICA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/25\">",
"     25",
"    </a>",
"    ]. Among over 200,000 patients who underwent surgery in 2007, 0.65 percent developed perioperative MICA. On multivariate logistic regression analysis, type of surgery, dependent functional status, abnormal creatinine, American Society of Anesthesiologists&rsquo; class (",
"    <a class=\"graphic graphic_table graphicRef56098 \" href=\"mobipreview.htm?8/33/8733\">",
"     table 7",
"    </a>",
"    ), and increased age were identified as predictors of MICA. A risk model was developed using these five risks factors and subsequently validated on a 2008 data set (n=257,385). The risk model had a relatively high predictive accuracy (C statistic of 0.874), and outperformed the RCRI (C statistic of 0.747). An easy to use calculator was developed from this model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Detsky modified risk index",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detsky and coworkers added angina and pulmonary edema to the original Goldman variables: unstable angina within three months prior to surgery, stable angina occurring with minimal physical activity, and recent pulmonary edema were assigned a high number of points, thereby contributing to an increased risk (",
"    <a class=\"graphic graphic_table graphicRef80422 \" href=\"mobipreview.htm?39/24/40332\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Detsky modification may not have sufficient discriminant power to identify significant coronary artery disease in patients at the lower end of the spectrum of clinical risk. Both indices may also underestimate cardiac risk in patients with vascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Eagle criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eagle and colleagues retrospectively studied 254 consecutive patients presenting to the nuclear cardiology laboratory for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    -thallium imaging before proposed vascular surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/13\">",
"     13",
"    </a>",
"    ]. Logistic regression analysis identified five clinical predictors of postoperative cardiac events in patients undergoing major vascular surgery:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Q waves on the ECG",
"     </li>",
"     <li>",
"      History of angina",
"     </li>",
"     <li>",
"      History of ventricular ectopy requiring treatment",
"     </li>",
"     <li>",
"      Diabetes mellitus requiring therapy other than diet",
"     </li>",
"     <li>",
"      Age above 70 years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent validation study added three more clinical predictors to the Eagle criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ischemic ST segment abnormalities on resting ECG",
"     </li>",
"     <li>",
"      Hypertension with severe left ventricular hypertrophy",
"     </li>",
"     <li>",
"      History of heart failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Logistic regression further identified two independent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    -thallium test predictors of ischemic events: thallium redistribution; and ischemic ECG changes during or after dipyridamole infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35192?source=see_link&amp;anchor=H4#H4\">",
"     \"Basic properties of myocardial perfusion agents\", section on 'Redistribution'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43081?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The original report and the prospective validation study demonstrated that noninvasive testing can be used to stratify intermediate to high risk vascular surgery patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/13,30\">",
"     13,30",
"    </a>",
"    ]. The original report suggested that lower risk patients with none or one of the five risk factors are likely to receive little benefit from noninvasive testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients at low risk are also highly unlikely to have severe and extensive coronary disease or critical stenoses on angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Fleisher-Eagle criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subsequent review by Fleisher and Eagle emphasized six factors, the first five of which are also in the revised cardiac risk index, associated with increased cardiac risk in patients undergoing noncardiac surgery, including vascular surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ischemic heart disease (angina or prior MI)",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      High-risk surgery (including intraperitoneal, intrathoracic, and suprainguinal vascular procedures)",
"     </li>",
"     <li>",
"      Diabetes mellitus (especially insulin-requiring)",
"     </li>",
"     <li>",
"      Renal insufficiency",
"     </li>",
"     <li>",
"      Poor functional status (defined as the inability to walk four blocks or climb two flights of stairs)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors recommended that further evaluation was required in patients with one or more of these risk factors. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Algorithmic approaches'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Aortic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the risk indices did not include aortic stenosis as a risk factor, probably because their sample populations did not include enough patients with the condition. However, moderate-to-severe aortic stenosis appears to be a significant risk factor for adverse cardiac outcomes after noncardiac surgery. In the original 1977 study of the Goldman cardiac risk index, for example, there were 23 patients with aortic stenosis (2.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/1\">",
"     1",
"    </a>",
"    ]. These patients had a 17.3 percent risk of cardiac complications and a 13 percent cardiac mortality. As a result, aortic stenosis was given a risk of 3 points.",
"   </p>",
"   <p>",
"    The approach to patients with aortic stenosis who need to undergo noncardiac surgery is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/14/13544?source=see_link\">",
"     \"Noncardiac surgery in patients with aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;When assessing preoperative cardiac risk, we prefer either the RCRI (",
"    <a class=\"graphic graphic_table graphicRef57075 \" href=\"mobipreview.htm?42/4/43083\">",
"     table 5",
"    </a>",
"    ) or the NSQIP risk model. The advantage of the RCRI is that it has been in use for over 10 years and many practitioners are familiar with it. The strengths of the NSQIP model include validation in a very large cohort, somewhat higher predictive accuracy than the RCRI, and development from a cohort of coronary artery disease patients treated with more recent preventative and revascularization strategies. Practitioners should become familiar with one model and use it regularly.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Revised cardiac risk index'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The use of estimated risk to determine whether further testing is indicated is discussed in the following sections. The use of this information for deciding whether preoperative interventions are indicated is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link\">",
"     \"Management of cardiac risk for noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     NONINVASIVE CARDIAC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above risk indices provide useful guidelines but are not sufficiently precise to estimate risk, particularly in patients at intermediate risk. Noninvasive testing with either stress testing, resting echocardiography, or both permits further stratification in patients deemed to be at intermediate risk after clinical evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following discussion supports two general conclusions about noninvasive testing with exercise or pharmacologic stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the purpose of predicting perioperative cardiac events, stress testing has a high negative predictive value (90 to 100 percent) but low positive predictive value (6 to 67 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/33\">",
"       33",
"      </a>",
"      ]. A 1995 review of 1410 selected patients referred for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      -thallium MPI prior to vascular surgery found a negative predictive value of 98 percent but a positive predictive value of only 18 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/2\">",
"       2",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The positive predictive value will be lower when positive tests are used to initiate therapies that prevent adverse cardiac outcomes, such as coronary revascularization, adjusting perioperative medical treatment and monitoring, or selecting different surgical procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/13\">",
"       13",
"      </a>",
"      ]. By comparison, the negative predictive value remains uniformly high (eg, as high as 98 to 99 percent with pharmacologic stress testing) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exercise is usually the preferred stress since, as noted below, exercise tolerance is an important predictor of outcome that appears to be more important than the ECG response. Pharmacologic stress testing can be used in patients who cannot exercise. Test performance and, in patients who cannot exercise, the choice between",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      -thallium radionuclide myocardial perfusion imaging and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      echocardiography are discussed below. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Choice of stress test'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of preoperative cardiac testing in intermediate risk patients (one to two RCRI risk factors) has been further elucidated by the DECREASE-II trial of 770 patients scheduled to undergo major vascular surgery (mostly for abdominal aortic aneurysm or peripheral artery disease) who were randomly assigned to pharmacologic stress testing or no testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients with positive tests and extensive ischemia could be managed with preoperative revascularization. All patients received perioperative beta blocker therapy, with dose adjustment with a goal resting heart rate between 60 to 65",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"   </p>",
"   <p>",
"    The incidence of the primary end point of cardiac death or nonfatal myocardial infarction at 30 days after surgery was similar between the non-testing and stress testing groups (1.8 versus 2.3 percent; odds ratio 0.78; 95% CI 0.3-2.1). The authors concluded that preoperative stress testing can be safely omitted in intermediate risk patients who have stable or no clinical coronary disease in whom beta blockers are given aiming at tight heart rate control. However, only 34 patients randomized to stress testing had extensive ischemia and few (six patients) had complete revascularization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Algorithmic approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an attempt to improve risk stratification, a number of algorithmic approaches have been proposed, all of which include stress testing in selected patients at increased risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/9,32,35-37\">",
"     9,32,35-37",
"    </a>",
"    ]. Perioperative risk stratification and management can characterize and possibly reduce risk, but will not eliminate it. Furthermore, no studies have been performed showing that use of these algorithms improves patient outcomes.",
"   </p>",
"   <p>",
"    Three major algorithms have been proposed by the",
"    <span class=\"nowrap\">",
"     ACC/AHA,",
"    </span>",
"    Fleisher and Eagle, and the American College of Physicians (ACP). The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines and the Fleisher-Eagle approach are largely based upon the criteria in the revised cardiac risk index (RCRI) (",
"    <a class=\"graphic graphic_table graphicRef57075 \" href=\"mobipreview.htm?42/4/43083\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Revised cardiac risk index'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      algorithm utilizes the presence or absence of active clinical conditions (eg, acute coronary syndrome or heart failure), the number of clinical risk factors (",
"      <a class=\"graphic graphic_table graphicRef62292 \" href=\"mobipreview.htm?26/56/27532\">",
"       table 1",
"      </a>",
"      ), functional capacity, and type of surgery (",
"      <a class=\"graphic graphic_table graphicRef57828 \" href=\"mobipreview.htm?7/2/7212\">",
"       table 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Fleisher-Eagle algorithm uses five of the six criteria in the RCRI, and substitutes a measure of functional status for a history of cerebrovascular disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ACP guidelines are based upon the Detsky modified risk index (",
"      <a class=\"graphic graphic_table graphicRef80422 \" href=\"mobipreview.htm?39/24/40332\">",
"       table 8",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ACP and Fleisher-Eagle approaches were derived from patients who were candidates for surgery; they did not include patients with high-risk conditions that were considered major predictors of risk in the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines; such patients require intensive management and often lead to delay in or cancellation of surgery (",
"    <a class=\"graphic graphic_table graphicRef62292 \" href=\"mobipreview.htm?26/56/27532\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Major predictors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The importance of underlying risk status as a determinant of the value of stress testing can be illustrated by the following calculations with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/33\">",
"     33",
"    </a>",
"    ], which has a reported sensitivity and specificity of 85 and 70 percent, respectively, for predicting perioperative death or nonfatal MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A patient with two RCRI risk factors may have a 2 percent pretest probability of a cardiac complication (",
"      <a class=\"graphic graphic_table graphicRef57075 \" href=\"mobipreview.htm?42/4/43083\">",
"       table 5",
"      </a>",
"      ). A positive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress test results in a modest increase in posttest probability to 5 percent.",
"     </li>",
"     <li>",
"      A patient with four RCRI risk factors may have a 9 percent pretest probability of a cardiac complication (",
"      <a class=\"graphic graphic_table graphicRef57075 \" href=\"mobipreview.htm?42/4/43083\">",
"       table 5",
"      </a>",
"      ). A positive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress test increases the posttest probability to about 20 percent, while a negative test reduces the posttest probability to about 2 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     ACC/AHA guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    (not changed in the 2009 focused update) recommended that the estimation of perioperative risk should integrate major, intermediate, and minor predictors of cardiac risk (",
"    <a class=\"graphic graphic_table graphicRef62292 \" href=\"mobipreview.htm?26/56/27532\">",
"     table 1",
"    </a>",
"    ), functional capacity (ie, metabolic equivalent [MET] or exercise duration), the surgery-specific risk (",
"    <a class=\"graphic graphic_table graphicRef57828 \" href=\"mobipreview.htm?7/2/7212\">",
"     table 2",
"    </a>",
"    ), and, when indicated, the results of noninvasive studies, including stress testing (",
"    <a class=\"graphic graphic_table graphicRef77115 \" href=\"mobipreview.htm?7/24/7564\">",
"     table 9",
"    </a>",
"    ) and (see",
"    <a class=\"local\" href=\"#H33\">",
"     'Choice of stress test'",
"    </a>",
"    below) and evaluation of left ventricular function (",
"    <a class=\"graphic graphic_table graphicRef65281 \" href=\"mobipreview.htm?34/2/34859\">",
"     table 10",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/9\">",
"     9",
"    </a>",
"    ]. Using this approach, only a minority of patients undergoing elective, as opposed to urgent or emergent surgery, will undergo preoperative noninvasive or invasive testing.",
"   </p>",
"   <p>",
"    The following points summarize the algorithm as it applies to STABLE patients. Patients with ACTIVE cardiac conditions (eg, unstable coronary syndromes, decompensated heart failure, significant arrhythmias, or severe valvular stenosis) not undergoing emergency surgery should first be managed according to",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients without active cardiac symptoms undergoing low risk surgery (",
"      <a class=\"graphic graphic_table graphicRef57828 \" href=\"mobipreview.htm?7/2/7212\">",
"       table 2",
"      </a>",
"      ) OR those with good functional capacity (MET level &ge;4) require no preoperative testing aside from an ECG (",
"      <a class=\"graphic graphic_table graphicRef53530 \" href=\"mobipreview.htm?19/6/19564\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with poor or unknown functional capacity, or potential cardiac symptoms who are scheduled to undergo intermediate risk or vascular surgery (",
"      <a class=\"graphic graphic_table graphicRef57828 \" href=\"mobipreview.htm?7/2/7212\">",
"       table 2",
"      </a>",
"      ) are managed according to the number of clinical risk factors (",
"      <a class=\"graphic graphic_table graphicRef62292 \" href=\"mobipreview.htm?26/56/27532\">",
"       table 1",
"      </a>",
"      ). For such patients, heart rate control with beta blockade may be of benefit. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link&amp;anchor=H44#H44\">",
"       \"Management of cardiac risk for noncardiac surgery\", section on 'Beta blockers'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with one or two clinical risk factors (",
"      <a class=\"graphic graphic_table graphicRef62292 \" href=\"mobipreview.htm?26/56/27532\">",
"       table 1",
"      </a>",
"      ), it is reasonable to proceed to surgery, unless testing will alter management",
"     </li>",
"     <li>",
"      In patients with three of more clinical risk factors scheduled to undergo intermediate risk surgery (",
"      <a class=\"graphic graphic_table graphicRef57828 \" href=\"mobipreview.htm?7/2/7212\">",
"       table 2",
"      </a>",
"      ), it is reasonable to proceed without noninvasive testing, unless that testing will alter management",
"     </li>",
"     <li>",
"      In patients with three or more clinical risk factors scheduled to undergo vascular surgery, the guidelines suggest noninvasive testing if it will alter management.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     ACP guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACP guidelines for assessing and managing perioperative risk are based upon the Detsky modified risk index (",
"    <a class=\"graphic graphic_table graphicRef80422 \" href=\"mobipreview.htm?39/24/40332\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/28\">",
"     28",
"    </a>",
"    ] and the results of noninvasive testing (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    thallium imaging or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Detsky modified risk index'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H23\">",
"     'Eagle criteria'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Fleisher-Eagle algorithm",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Fleisher-Eagle criteria emphasized six factors associated with increased cardiac risk in patients undergoing noncardiac surgery, including vascular surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/32\">",
"     32",
"    </a>",
"    ]. Five of these factors were also in the revised cardiac risk index. The Fleisher-Eagle algorithm is virtually identical to a subsequent algorithm by Auerbach and Goldman that used the revised cardiac risk index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Fleisher-Eagle criteria'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The authors recommended that patients with none of the risk factors required no further testing or treatment, while further evaluation was required in other patients. Those with one or two risk factors should be further evaluated to determine if a history consistent with coronary heart disease is present. If such a history is absent, perioperative beta blocker therapy is prudent, but no further testing is recommended. For patients with a history consistent with coronary disease, and for those with three or more of the above risk factors, noninvasive testing should be performed, followed by cardiac catheterization if the results are positive.",
"   </p>",
"   <p>",
"    In this and other approaches, the algorithm can also identify patients who might benefit from beta blocker therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/32,33,37\">",
"     32,33,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link&amp;anchor=H44#H44\">",
"     \"Management of cardiac risk for noncardiac surgery\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Choice of stress test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise ECG testing is usually the preferred stress test since, as noted below, exercise tolerance is an important predictor of outcome that appears to be more important than the ECG response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/2,39,40\">",
"     2,39,40",
"    </a>",
"    ]. Exercise ECG testing is usually performed with perfusion imaging or echocardiography since imaging can better identify high-risk features that would warrant referral for angiography (eg, reversible large anterior wall defect, multiple reversible defects, ischemia occurring at a low heart rate, extensive stress-induced wall motion abnormalities, transient ischemic dilatation).",
"   </p>",
"   <p>",
"    In addition, concurrent imaging is essential if the resting ECG has abnormalities that can interfere with the detection of ischemia during exercise stress. These include preexcitation (Wolff-Parkinson-White) syndrome, a paced ventricular rhythm, more than 1 mm of ST depression at rest, complete left bundle branch block, and patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    or with ECG criteria for left ventricular hypertrophy, even if they have less than 1 mm of baseline ST depression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A possible exception to the preference for exercise stress occurs in patients with an aortic aneurysm, since exercise increases systolic pressure and heart rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/41\">",
"     41",
"    </a>",
"    ]. Despite this theoretical concern, exercise stress appears to be safe in patients with abdominal aortic aneurysms, particularly those less than 6.0 cm in diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/41\">",
"     41",
"    </a>",
"    ]. Pharmacologic stress testing is preferred in patients with abdominal aortic aneurysms &ge;6.0 cm in diameter or aneurysms that are symptomatic. It is appropriate to control hypertension prior to stress testing in patients with aneurysms.",
"   </p>",
"   <p>",
"    Limited data exist upon which to make recommendations for stress testing in patients with thoracic aortic aneurysms, but a similar approach to that for abdominal aortic aneurysms seems reasonable.",
"   </p>",
"   <p>",
"    Among patients who cannot exercise sufficiently to reach the target heart rate (eg, those who are not limited by claudication, orthopedic degenerative joint disease, or severe deconditioning), the two most widely used alternatives are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    -thallium radionuclide myocardial perfusion imaging (rMPI) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography.",
"   </p>",
"   <p>",
"    A meta-analysis evaluated the sensitivity and specificity of the different noninvasive tests for predicting perioperative death or nonfatal MI in patients undergoing major vascular surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/38\">",
"     38",
"    </a>",
"    ]. The following values were obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise ECG &mdash; sensitivity 74 percent, specificity 69 percent",
"     </li>",
"     <li>",
"      rMPI, mostly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      stress &mdash; sensitivity 83 percent, specificity 49 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       Dobutamine",
"      </a>",
"      echocardiography &mdash; sensitivity 85 percent, specificity 70 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these findings should be interpreted with caution because the majority of studies in the meta-analysis were not well designed, there was significant heterogeneity in the results for individual tests, and the results were analyzed as either negative or positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When pharmacologic stress testing is indicated, the choice between tests should be based upon local experience and availability and the relative safety of the different procedures in the individual patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       Dipyridamole",
"      </a>",
"      -thallium imaging is usually preferred in patients with known cardiac arrhythmias, since",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      can induce atrial or ventricular arrhythmias.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       Dobutamine",
"      </a>",
"      echocardiography is preferred in patients with bronchospastic lung disease and in those with severe carotid stenosis, because",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      can induce bronchospasm and a decrease in blood pressure. It is also preferred when information about left ventricular function or valvular heart disease is desired [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/33\">",
"       33",
"      </a>",
"      ]. Dobutamine appears to be safe in patients with abdominal aortic aneurysms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stress testing has a very high negative predictive value for postoperative cardiovascular events (between 90 and 100 percent) but a low positive predictive value (between 6 and 67 percent, with a value of 18 percent in a review of five large studies of thallium perfusion imaging) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/2,33\">",
"     2,33",
"    </a>",
"    ]. Thus, stress testing is more useful for reducing estimated risk if negative (or normal) than for identifying patients at very high risk if positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Exercise stress testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise stress testing without myocardial imaging is the standard method for determining functional capacity and for the detection of myocardial ischemia. Exercise tolerance appears to be more important than the ECG response to exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/2,39,40\">",
"     2,39,40",
"    </a>",
"    ]. Inability to perform moderate exercise or to achieve greater than 85 percent of predicted maximal heart rate during exercise treadmill testing is associated with a high risk of a postoperative cardiac event, even in the absence of diagnostic ischemic ECG changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are, however, a number of limitations to exercise stress testing in assessing cardiac risk prior to noncardiac surgery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many patients are unable to exercise or unable to exercise to their target heart rate due to leg claudication, arthritis, deconditioning, or associated pulmonary disease.",
"     </li>",
"     <li>",
"      Patients with resting ECG abnormalities may require imaging to detect myocardial ischemia.",
"     </li>",
"     <li>",
"      The sensitivity of exercise testing in detecting coronary artery disease is lower with submaximal than with maximal exercise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Exercise stress testing can be coupled with respiratory gas analysis (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33398?source=see_link\">",
"     \"Functional exercise testing: Ventilatory gas analysis\"",
"    </a>",
"    ) and this is often referred to as cardiopulmonary exercise testing. Although cardiopulmonary exercise testing has been advocated to assess functional capacity and to guide prognosis for patients undergoing major noncardiac vascular surgery, a 2012 meta-analysis of six observational studies with significant limitations found insufficient evidence to support its use in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Pharmacologic stress testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologically-induced cardiac stress testing is warranted in patients who cannot exercise and have abnormalities on the baseline ECG that interfere with interpretation. The two most common used tests are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    -thallium radionuclide myocardial perfusion imaging and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43081?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=see_link\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Dipyridamole rMPI",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have evaluated the predictive value of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    -thallium imaging in patients undergoing major noncardiac surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/2,13,30,45-55\">",
"     2,13,30,45-55",
"    </a>",
"    ]. In a 1995 review of the five largest series of 1410 selected patients referred for dipyridamole-thallium rMPI prior to vascular surgery, the sensitivity and specificity for a major cardiac event was 85 and 60 percent, respectively, while the relative risk for a cardiac event in patients with a positive test was 9.0 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/2\">",
"     2",
"    </a>",
"    ]. The negative predictive value of dipyridamole-thallium imaging was 98 percent, but the positive predictive value was only 18 percent. Thus, a positive test is a relatively weak predictor of a perioperative cardiac event.",
"   </p>",
"   <p>",
"    The ability to identify patients at risk may be increased when taking into account the extent of ischemia rather than only its presence. This was illustrated in a meta-analysis of nine studies that evaluated the probability of MI or cardiac death after vascular surgery according to the extent of reversible myocardial defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/56\">",
"     56",
"    </a>",
"    ]. The probability of MI or cardiac death without reperfusion ranged from 3 to 4 percent in patients with no or only fixed defects to 9 percent with reversible defects involving less than 20 percent of the left ventricle to 18 and 45 percent with reversible defects involving 30 to 49 percent and &ge;50 percent of the left ventricle, respectively. However, most of the studies were deemed to be of low quality.",
"   </p>",
"   <p>",
"    Other studies showed that the specificity can be increased by testing in subgroups at intermediate risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/13,51\">",
"     13,51",
"    </a>",
"    ] or by measuring the amount of myocardium at risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/50,54\">",
"     50,54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The potential value of stress testing was illustrated in a report in which 18 of 116 patients with one or two Eagle predictors who were undergoing major vascular surgery had cardiac ischemic events in the early postoperative period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/13\">",
"       13",
"      </a>",
"      ]. Among these 116 patients, the rate of events was much higher in the 54 patients with thallium redistribution compared to the 62 without thallium redistribution (30 versus 3 percent). Use of both clinical and thallium variables had significantly higher specificity and equivalent sensitivity compared to predictions from clinical or thallium variables alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar increase in risk of a perioperative event with a reversible thallium defect in one or more segments was noted in a series of 161 patients with an intermediate to high risk of coronary disease (27 versus 6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The importance of the extent of jeopardized myocardium was illustrated in a study of 355 patients undergoing vascular and major general surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/54\">",
"       54",
"      </a>",
"      ]. The rate of postoperative events varied from 1.3 percent in the 225 patients with a normal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      -thallium study to 52 percent in the 29 patients with reversible defects in all three segments, at least one severe reversible defect, or transient left ventricular dilation. Among the 101 patients with one or two reversible defects, the rate of cardiac events ranged from 5 to 36 percent depending upon the number of defects, age greater than 70, and the presence of diabetes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The predictive value of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    -thallium rMPI may also be improved by concurrent echocardiography to detect a reduced left ventricular ejection fraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H38\">",
"     'Resting echocardiography'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In contrast to these findings, a prospective study of 457 consecutive (unselected) patients undergoing elective abdominal aortic surgery did not confirm the usefulness of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    -thallium scintigraphy in stratifying unselected patients with definitive evidence of coronary artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/14\">",
"     14",
"    </a>",
"    ]. However, a number of methodological issues may make these results less applicable for many patients undergoing abdominal aortic surgery. High-risk patients (such as those with severe coronary disease) and patients undergoing revascularization were excluded, and the population of patients selected appeared to represent a low-risk group. Furthermore, invasive perioperative monitoring was used in all patients, a regimen that differs from general practice.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use in risk model &mdash; A risk prediction model was developed for patients considered for vascular surgery that included the results of radionuclide myocardial perfusion imaging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/57\">",
"       57",
"      </a>",
"      ]. The model was retrospectively developed based upon 567 patients and validated prospectively in 514 patients. A risk score was derived using clinical variables including:",
"     </li>",
"     <li>",
"      Age &gt;70",
"     </li>",
"     <li>",
"      Angina",
"     </li>",
"     <li>",
"      History of MI",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      History of HF",
"     </li>",
"     <li>",
"      Prior coronary revascularization within five years, which was given a negative weight since it is protective",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A second model was based upon",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    -thallium predictors of myocardial infarction, ie, fixed and reversible myocardial defects. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prognostic accuracy was 74 percent for the clinical and 81 percent for the clinical and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      model.",
"     </li>",
"     <li>",
"      Using the clinical model, the postoperative event rate was 3, 8, and 18 percent for patients classified as low, moderate, and high risk. Addition of the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      -thallium scan reclassified the moderate risk patients into low (3 percent) and high (19 percent) risk categories. The scan provided no additional help for patients classified as low or high risk based upon clinical parameters.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Dobutamine echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    stress echocardiography (DSE) has a discriminant ability in vascular and nonvascular surgery patients that is similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    -thallium studies and provides additional information about valvular anatomy and resting and stress systolic function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=see_link\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Role in vascular surgery &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       Dobutamine",
"      </a>",
"      stress echocardiography (DSE) is an alternative accepted method for preoperative assessment of cardiac risk in patients undergoing vascular surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/58-62\">",
"       58-62",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The potential efficacy was illustrated in a study of 316 patients undergoing vascular surgery who had preoperative DSE and were followed for 19 months postoperatively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/59\">",
"       59",
"      </a>",
"      ]. Using a multivariate regression analysis, the occurrence of extensive (three or more segments) or limited (one or two segments) stress-induced new wall motion abnormalities on DSE, and a history of previous MI independently predicted late cardiac events, increasing the risk by 6.5, 2.9, and 3.8 fold, respectively (",
"      <a class=\"graphic graphic_figure graphicRef77763 \" href=\"mobipreview.htm?32/45/33501\">",
"       figure 2",
"      </a>",
"      ). The severity of ischemia during stress and the threshold heart rate for ischemia were not predictive in this study, but have been important in other studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/58,62\">",
"       58,62",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The predictive value of DSE appears to vary with patient risk, having limited utility in patients at very low risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/58\">",
"       58",
"      </a>",
"      ] and in lower risk patients taking a beta blocker [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/62\">",
"       62",
"      </a>",
"      ]. This was illustrated in an analysis of 1097 patients in which DSE did not provide additional prognostic information among those estimated to be at low risk (less than three clinical risk factors using the Eagle criteria cited above) who were treated with a beta blocker (",
"      <a class=\"graphic graphic_figure graphicRef62668 \" href=\"mobipreview.htm?15/49/16159\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/62\">",
"       62",
"      </a>",
"      ]. In contrast, DSE provided additional prognostic information in patients who had three or more clinical risk factors. In addition, patients with &ge;5 segments involved had more cardiac events than those with limited stress-induced ischemia (one to four segments) (36 versus 3 percent). Among such patients taking a beta blocker, those with stress-induced ischemia had a significantly higher risk of a cardiac event at 30 days (10.6 versus 2 percent without ischemia) (",
"      <a class=\"graphic graphic_figure graphicRef62668 \" href=\"mobipreview.htm?15/49/16159\">",
"       figure 3",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Hypotension during DSE is another factor associated with an adverse cardiovascular outcome (cardiac death, infarction, and ischemia) in the perioperative period. In one series of 300 patients, a hypotensive response was observed in 28 percent; with a multivariate analysis, hypotension was a significant predictor of a cardiac event (odds ratio 4.1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/60\">",
"       60",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A potential concern with dobutamine echocardiography is the safety of increasing cardiac output and blood pressure in patients with an abdominal aneurysm. In a series of 98 such patients, there were no serious complications with its use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/43\">",
"       43",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Role in nonvascular surgery &mdash; Data are more limited concerning the utility of DSE for risk stratification before nonvascular surgery. The likelihood of coexistent coronary heart disease in this more general population is probably lower than among those undergoing vascular surgery. This issue was addressed in a report of 530 patients who underwent DSE before nonvascular surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/63\">",
"       63",
"      </a>",
"      ]. The following findings were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A postoperative cardiac event occurred in 6 percent (31 nonfatal MIs and one cardiac death), all of whom had inducible ischemia on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      echocardiography. The sensitivity and specificity of DSE were 100 and 63 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DSE identified 60 percent of patients as low risk (no ischemia), 32 percent as intermediate risk (ischemia at &ge;60 percent of age predicted maximal heart rate), and 8 percent as high risk (ischemia at &lt;60 percent of maximal heart rate). The postoperative event rates in these three groups were 0, 9, and 43 percent, respectively. In contrast, use of the Eagle criteria identified 21, 68, and 11 percent of patients as low, intermediate, or high risk; the event rates were 3, 6, and 14 percent, respectively. Thus, DSE added incremental value to the Eagle criteria in identifying patients at high risk. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Eagle criteria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Resting echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resting transthoracic echocardiography (TTE) may add predictive information in certain patients undergoing noncardiac surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/53,64\">",
"     53,64",
"    </a>",
"    ]. TTE can assess left ventricular systolic function, including the effect of a prior MI, and evaluate possible valvular heart disease, such as aortic stenosis. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Aortic stenosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Potential utility of resting TTE was suggested in a study of 570 patients who underwent TTE within three months of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/64\">",
"     64",
"    </a>",
"    ]. In a multivariate model that included both clinical and echocardiographic variables, TTE findings of systolic dysfunction, moderate to severe left ventricular hypertrophy, and a peak aortic valve gradient of &ge;40 mmHg were associated with odds ratios for major cardiac events of 2.0, 2.1, and 6.8, respectively.",
"   </p>",
"   <p>",
"    However, other studies have found that measurement of left ventricular ejection fraction was useful only for the prediction of heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/14\">",
"     14",
"    </a>",
"    ] and that resting TTE does not add appreciably to the information obtained in the clinical risk models described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/2,65\">",
"     2,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main indications for preoperative resting TTE are similar to those in nonsurgical patients (eg, to evaluate valve function in patients with a murmur or left ventricular systolic function, especially in patients with heart failure of unknown cause) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery (not changed in the 2009 focused update) recommended assessment of LV function in patients with current heart failure or prior heart failure with worsening dyspnea, as well as those with dyspnea of unknown origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H538698649\">",
"    <span class=\"h2\">",
"     Troponin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential role of troponin testing in perioperative risk stratification is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29975?source=see_link&amp;anchor=H378922#H378922\">",
"     \"Perioperative myocardial infarction after noncardiac surgery\", section on 'Biomarker testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Ischemia monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with known or at high risk for coronary heart disease who undergo preoperative ambulatory ECG monitoring, 20 to 40 percent have frequent and often silent episodes of myocardial ischemia during the 48 hours before surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/2,66-68\">",
"     2,66-68",
"    </a>",
"    ]. Such patients appear to be at increased risk for adverse cardiac outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. On the other hand, the absence of preoperative or immediate postoperative ischemic ST-segment depression on continuous electrocardiographic monitoring for 24 to 48 hours has been associated with a very low postoperative cardiac event rate in vascular surgery patients otherwise determined to be at intermediate to high risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, it is not clear if ischemia monitoring is sufficiently sensitive to identify patients at low risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/2,68\">",
"     2,68",
"    </a>",
"    ]. In addition, the usefulness of this test in the general population is limited because the above reports excluded patients with ECG findings that preclude accurate evaluation for ischemia (left bundle branch block, left ventricular hypertrophy with \"strain\" pattern, or digitalis effect).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The process of estimating and reducing the risk of perioperative cardiac events (eg, cardiac death and nonfatal MI), includes the following four components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Defining the urgency of surgery. For instance, risk assessment may not alter the management of patients who need emergency surgery. (See",
"      <a class=\"local\" href=\"#H46\">",
"       'Urgency of surgery'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Initial risk assessment.",
"     </li>",
"     <li>",
"      Refinement of initial risk assessment with noninvasive testing in selected patients.",
"     </li>",
"     <li>",
"      Efforts to reduce risk in high-risk patients (eg, beta blockers, revascularization). These therapeutic issues and those related to the perioperative evaluation and management of heart failure in relation to noncardiac surgery are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link\">",
"       \"Management of cardiac risk for noncardiac surgery\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18440?source=see_link\">",
"       \"Perioperative heart failure in noncardiac surgery\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Initial risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial risk assessment consists of three steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Does the patient have a high-risk condition that is considered a major predictor of risk in the",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery (not changed in the 2009 focused update) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/9\">",
"       9",
"      </a>",
"      ]? Such patients require intensive management and often a delay in or cancellation of surgery. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Major predictors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      What is the surgery-specific risk of the planned operation?",
"     </li>",
"     <li>",
"      What is the patient-specific risk?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The indices described above all combine surgery- and patient-specific risks to provide an initial estimate of operative risk. We and others suggest the revised cardiac risk index (RCRI). It is the best validated risk index, is simple to use, and it appears to have greater predictive value than the original Goldman and Detsky risk indices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/7,17,69\">",
"     7,17,69",
"    </a>",
"    ]. However, as discussed above, it may underestimate a patient's true risk. We believe that the use of the NSQIP database risk model, is also a reasonable alternative. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Revised cardiac risk index'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Refinement of initial risk estimate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial risk estimate derived from one of the above indices is often adequate to guide decisions regarding perioperative management. However, it is helpful in some cases to refine this estimate with noninvasive stress testing. In selected patients, the results of noninvasive testing will affect both the timing of surgery and the need for preoperative revascularization.",
"   </p>",
"   <p>",
"    The algorithmic approaches cited above provide strategies to determine which patients require additional risk stratification prior to surgery, with indications for noninvasive testing and cardiac catheterization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/9,32,33,35,36\">",
"     9,32,33,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We prefer either the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines or the Fleisher-Eagle algorithm, because the predictors used largely overlap with the revised cardiac risk index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/9,32\">",
"     9,32",
"    </a>",
"    ]. A subsequent algorithm from Auerbach and Goldman is virtually identical to the Fleisher-Eagle algorithm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Algorithmic approaches'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The Fleisher-Eagle algorithm is easier to use, but refers only to patients who are candidates for surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/32\">",
"     32",
"    </a>",
"    ]. It does not include patients with high-risk conditions that are considered major predictors of risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Major predictors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Stress testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for preoperative stress testing are based upon clinical risk factors, functional capacity, and the surgery-specific risk. The 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines concluded that the evidence was in favor of benefit of preoperative stress testing for [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients deemed to be at high risk (&ge;3 revised cardiac index criteria) and with poor functional capacity (&lt;4 METS) who are scheduled for vascular surgery when such testing will change management.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evidence was considered less well established for the benefit of preoperative stress testing in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with at least one clinical risk factor and poor functional capacity (&lt;4 METS) who are scheduled for intermediate-risk surgery when such testing will change management",
"     </li>",
"     <li>",
"      Patients with at least one clinical risk factor and good functional capacity (&ge;4 METS) who are scheduled for vascular surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stress testing has a very high negative predictive value for postoperative cardiovascular events (between 90 and 100 percent) but a low positive predictive value (between 6 and 67 percent, with a value of 18 percent in a review of five large studies of thallium perfusion imaging) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/2,33\">",
"     2,33",
"    </a>",
"    ]. Thus, stress testing is more useful for reducing estimated risk if negative (or normal) than for identifying patients at very high risk when positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When stress testing is performed, patients who are able to exercise sufficiently to reach the target heart rate (eg, those who are not limited by claudication, orthopedic degenerative joint disease, or severe deconditioning) can undergo exercise ECG testing often with concurrent imaging to better identify high-risk features that would warrant referral for angiography (eg, reversible large anterior wall defect, multiple reversible defects, ischemia occurring at a low heart rate, extensive stress-induced wall motion abnormalities, transient ischemic dilatation).",
"   </p>",
"   <p>",
"    In addition, concurrent imaging is essential if the ECG has abnormalities that interfere with interpretation of exercise stress, exercise perfusion imaging or echocardiography. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are unable to ambulate sufficiently to increase their cardiovascular workload should undergo pharmacologic stress with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    -thallium rMPI or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography. The choice of test should be based upon local experience and availability and the relative safety of the different procedures in the individual patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Choice of stress test'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Resting echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest resting echocardiography to quantify valvular dysfunction in patients with a murmur, to evaluate ventricular dysfunction in poorly controlled HF or in dyspnea of uncertain cause, or to evaluate for possible pulmonary hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/33\">",
"     33",
"    </a>",
"    ]. Routine echocardiography is not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/9,33\">",
"     9,33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H38\">",
"     'Resting echocardiography'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Preoperative revascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proportion of noncardiac surgery patients who undergo preoperative cardiac catheterization and revascularization appears to be very low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/69\">",
"     69",
"    </a>",
"    ]. In three studies that used the approach in the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines, 2 to 11 percent of patients underwent coronary angiography and only 0 to 2 percent underwent preoperative revascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. The rate of intervention may be even lower in asymptomatic patients, since these studies included symptomatic patients who may have been more likely to undergo revascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings indicate that there are few asymptomatic intermediate-risk patients who are candidates for preoperative revascularization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of cardiac risk for noncardiac surgery\", section on 'Revascularization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Urgency of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above approach to cardiac risk stratification primarily applies to elective surgery. In this setting there is adequate time to complete recommended tests and, if necessary, revascularization procedures. If preoperative PCI is considered, any potential benefit must be balanced against the requirements for a full course of aggressive antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . Premature discontinuation of antiplatelet therapy carries a substantial risk of stent thrombosis, a risk that may be increased further by surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link&amp;anchor=H9#H9\">",
"     \"Management of cardiac risk for noncardiac surgery\", section on 'Preoperative PCI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h3\">",
"     Emergent surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergent surgery carries unique, often substantial risks. In these cases, risk indices derived from elective surgery cohorts are not accurate, although they may provide an estimate of the minimal risk. Further testing and interventions are unlikely to be beneficial. Despite the elevated risk, patients are usually best served by proceeding directly to surgery. Beta blockers may be helpful in patients who are hemodynamically stable and in whom benefit has been shown. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link&amp;anchor=H44#H44\">",
"     \"Management of cardiac risk for noncardiac surgery\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h3\">",
"     Urgent surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;For urgent surgery (eg, required during the same admission but a delay of days may be acceptable), initial risk estimates should be made. However, the value of additional testing and treatment is often limited except for identifying and stabilizing patients with unstable cardiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/60/36810/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Such patients are usually not candidates for CABG and the need for prolonged dual antiplatelet therapy markedly limits the use of PCI. The main option for risk reduction is a beta blocker, and recommendations are often made on the basis of initial risk indices. If the surgical approach would be altered on the basis of additional risk stratification (eg, surgery would be delayed, canceled, or performed on dual antiplatelet therapy), additional testing and treatment may be warranted.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/1\">",
"      Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med 1977; 297:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/2\">",
"      Mangano DT, Goldman L. Preoperative assessment of patients with known or suspected coronary disease. N Engl J Med 1995; 333:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/3\">",
"      Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/4\">",
"      Wong T, Detsky AS. Preoperative cardiac risk assessment for patients having peripheral vascular surgery. Ann Intern Med 1992; 116:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/5\">",
"      Kelly R, Staines A, MacWalter R, et al. The prevalence of treatable left ventricular systolic dysfunction in patients who present with noncardiac vascular episodes: a case-control study. J Am Coll Cardiol 2002; 39:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/6\">",
"      Stampfer MJ, Grodstein F, Bechtel S. Postmenopausal estrogen and cardiovascular disease. Contemp Intern Med 1994; 6:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/7\">",
"      Devereaux PJ, Goldman L, Cook DJ, et al. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ 2005; 173:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/8\">",
"      Lindenauer PK, Pekow P, Wang K, et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 2005; 353:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/9\">",
"      Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2009; 120:e169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/10\">",
"      Eagle KA, Berger PB, Calkins H, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Coll Cardiol 2002; 39:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/11\">",
"      Girish M, Trayner E Jr, Dammann O, et al. Symptom-limited stair climbing as a predictor of postoperative cardiopulmonary complications after high-risk surgery. Chest 2001; 120:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/12\">",
"      Reilly DF, McNeely MJ, Doerner D, et al. Self-reported exercise tolerance and the risk of serious perioperative complications. Arch Intern Med 1999; 159:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/13\">",
"      Eagle KA, Coley CM, Newell JB, et al. Combining clinical and thallium data optimizes preoperative assessment of cardiac risk before major vascular surgery. Ann Intern Med 1989; 110:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/14\">",
"      Baron JF, Mundler O, Bertrand M, et al. Dipyridamole-thallium scintigraphy and gated radionuclide angiography to assess cardiac risk before abdominal aortic surgery. N Engl J Med 1994; 330:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/15\">",
"      van Klei WA, Bryson GL, Yang H, et al. The value of routine preoperative electrocardiography in predicting myocardial infarction after noncardiac surgery. Ann Surg 2007; 246:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/16\">",
"      Rao TL, Jacobs KH, El-Etr AA. Reinfarction following anesthesia in patients with myocardial infarction. Anesthesiology 1983; 59:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/17\">",
"      Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999; 100:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/18\">",
"      van Diepen S, Bakal JA, McAlister FA, Ezekowitz JA. Mortality and readmission of patients with heart failure, atrial fibrillation, or coronary artery disease undergoing noncardiac surgery: an analysis of 38 047 patients. Circulation 2011; 124:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/19\">",
"      Poirier P, Alpert MA, Fleisher LA, et al. Cardiovascular evaluation and management of severely obese patients undergoing surgery: a science advisory from the American Heart Association. Circulation 2009; 120:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/20\">",
"      Mangano DT. Perioperative cardiac morbidity. Anesthesiology 1990; 72:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/21\">",
"      Weitz H, Merli G. Invasive dental treatment and risk for vascular events: have we bitten off more than we can chew? Ann Intern Med 2010; 153:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/22\">",
"      Minassian C, D'Aiuto F, Hingorani AD, Smeeth L. Invasive dental treatment and risk for vascular events: a self-controlled case series. Ann Intern Med 2010; 153:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/23\">",
"      Ford MK, Beattie WS, Wijeysundera DN. Systematic review: prediction of perioperative cardiac complications and mortality by the revised cardiac risk index. Ann Intern Med 2010; 152:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/24\">",
"      POISE Study Group, Devereaux PJ, Yang H, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008; 371:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/25\">",
"      Gupta PK, Gupta H, Sundaram A, et al. Development and validation of a risk calculator for prediction of cardiac risk after surgery. Circulation 2011; 124:381.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.surgicalriskcalculator.com/miorcardiacarrest.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/27\">",
"      Detsky AS, Abrams HB, McLaughlin JR, et al. Predicting cardiac complications in patients undergoing non-cardiac surgery. J Gen Intern Med 1986; 1:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/28\">",
"      Detsky AS, Abrams HB, Forbath N, et al. Cardiac assessment for patients undergoing noncardiac surgery. A multifactorial clinical risk index. Arch Intern Med 1986; 146:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/29\">",
"      Younis LT, Miller DD, Chaitman BR. Preoperative strategies to assess cardiac risk before noncardiac surgery. Clin Cardiol 1995; 18:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/30\">",
"      Vanzetto G, Machecourt J, Blendea D, et al. Additive value of thallium single-photon emission computed tomography myocardial imaging for prediction of perioperative events in clinically selected high cardiac risk patients having abdominal aortic surgery. Am J Cardiol 1996; 77:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/31\">",
"      Paul SD, Eagle KA, Kuntz KM, et al. Concordance of preoperative clinical risk with angiographic severity of coronary artery disease in patients undergoing vascular surgery. Circulation 1996; 94:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/32\">",
"      Fleisher LA, Eagle KA. Clinical practice. Lowering cardiac risk in noncardiac surgery. N Engl J Med 2001; 345:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/33\">",
"      Auerbach A, Goldman L. Assessing and reducing the cardiac risk of noncardiac surgery. Circulation 2006; 113:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/34\">",
"      Poldermans D, Bax JJ, Schouten O, et al. Should major vascular surgery be delayed because of preoperative cardiac testing in intermediate-risk patients receiving beta-blocker therapy with tight heart rate control? J Am Coll Cardiol 2006; 48:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/35\">",
"      Guidelines for assessing and managing the perioperative risk from coronary artery disease associated with major noncardiac surgery. American College of Physicians. Ann Intern Med 1997; 127:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/36\">",
"      Palda VA, Detsky AS. Perioperative assessment and management of risk from coronary artery disease. Ann Intern Med 1997; 127:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/37\">",
"      Grayburn PA, Hillis LD. Cardiac events in patients undergoing noncardiac surgery: shifting the paradigm from noninvasive risk stratification to therapy. Ann Intern Med 2003; 138:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/38\">",
"      Kertai MD, Boersma E, Bax JJ, et al. A meta-analysis comparing the prognostic accuracy of six diagnostic tests for predicting perioperative cardiac risk in patients undergoing major vascular surgery. Heart 2003; 89:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/39\">",
"      Gerson MC, Hurst JM, Hertzberg VS, et al. Cardiac prognosis in noncardiac geriatric surgery. Ann Intern Med 1985; 103:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/40\">",
"      McPhail N, Calvin JE, Shariatmadar A, et al. The use of preoperative exercise testing to predict cardiac complications after arterial reconstruction. J Vasc Surg 1988; 7:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/41\">",
"      Best PJ, Tajik AJ, Gibbons RJ, Pellikka PA. The safety of treadmill exercise stress testing in patients with abdominal aortic aneurysms. Ann Intern Med 1998; 129:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/42\">",
"      Johns JP, Abraham SA, Eagle KA. Dipyridamole-thallium versus dobutamine echocardiographic stress testing: a clinician's viewpoint. Am Heart J 1995; 130:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/43\">",
"      Pellikka PA, Roger VL, Oh JK, et al. Safety of performing dobutamine stress echocardiography in patients with abdominal aortic aneurysm &gt; or = 4 cm in diameter. Am J Cardiol 1996; 77:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/44\">",
"      Young EL, Karthikesalingam A, Huddart S, et al. A systematic review of the role of cardiopulmonary exercise testing in vascular surgery. Eur J Vasc Endovasc Surg 2012; 44:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/45\">",
"      Eagle KA, Singer DE, Brewster DC, et al. Dipyridamole-thallium scanning in patients undergoing vascular surgery. Optimizing preoperative evaluation of cardiac risk. JAMA 1987; 257:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/46\">",
"      Coley CM, Field TS, Abraham SA, et al. Usefulness of dipyridamole-thallium scanning for preoperative evaluation of cardiac risk for nonvascular surgery. Am J Cardiol 1992; 69:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/47\">",
"      Cutler BS, Leppo JA. Dipyridamole thallium 201 scintigraphy to detect coronary artery disease before abdominal aortic surgery. J Vasc Surg 1987; 5:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/48\">",
"      Boucher CA, Brewster DC, Darling RC, et al. Determination of cardiac risk by dipyridamole-thallium imaging before peripheral vascular surgery. N Engl J Med 1985; 312:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/49\">",
"      Lette J, Waters D, Bernier H, et al. Preoperative and long-term cardiac risk assessment. Predictive value of 23 clinical descriptors, 7 multivariate scoring systems, and quantitative dipyridamole imaging in 360 patients. Ann Surg 1992; 216:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/50\">",
"      Brown KA, Rowen M. Extent of jeopardized viable myocardium determined by myocardial perfusion imaging best predicts perioperative cardiac events in patients undergoing noncardiac surgery. J Am Coll Cardiol 1993; 21:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/51\">",
"      Younis L, Stratmann H, Takase B, et al. Preoperative clinical assessment and dipyridamole thallium-201 scintigraphy for prediction and prevention of cardiac events in patients having major noncardiovascular surgery and known or suspected coronary artery disease. Am J Cardiol 1994; 74:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/52\">",
"      Stratmann HG, Younis LT, Wittry MD, et al. Dipyridamole technetium 99m sestamibi myocardial tomography for preoperative cardiac risk stratification before major or minor nonvascular surgery. Am Heart J 1996; 132:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/53\">",
"      Kontos MC, Brath LK, Akosah KO, Mohanty PK. Cardiac complications in noncardiac surgery: relative value of resting two-dimensional echocardiography and dipyridamole thallium imaging. Am Heart J 1996; 132:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/54\">",
"      Lette J, Waters D, Cerino M, et al. Preoperative coronary artery disease risk stratification based on dipyridamole imaging and a simple three-step, three-segment model for patients undergoing noncardiac vascular surgery or major general surgery. Am J Cardiol 1992; 69:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/55\">",
"      Landesberg G, Mosseri M, Shatz V, et al. Cardiac troponin after major vascular surgery: the role of perioperative ischemia, preoperative thallium scanning, and coronary revascularization. J Am Coll Cardiol 2004; 44:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/56\">",
"      Etchells E, Meade M, Tomlinson G, Cook D. Semiquantitative dipyridamole myocardial stress perfusion imaging for cardiac risk assessment before noncardiac vascular surgery: a meta-analysis. J Vasc Surg 2002; 36:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/57\">",
"      L'Italien GJ, Paul SD, Hendel RC, et al. Development and validation of a Bayesian model for perioperative cardiac risk assessment in a cohort of 1,081 vascular surgical candidates. J Am Coll Cardiol 1996; 27:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/58\">",
"      Poldermans D, Arnese M, Fioretti PM, et al. Improved cardiac risk stratification in major vascular surgery with dobutamine-atropine stress echocardiography. J Am Coll Cardiol 1995; 26:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/59\">",
"      Poldermans D, Arnese M, Fioretti PM, et al. Sustained prognostic value of dobutamine stress echocardiography for late cardiac events after major noncardiac vascular surgery. Circulation 1997; 95:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/60\">",
"      Day SM, Younger JG, Karavite D, et al. Usefulness of hypotension during dobutamine echocardiography in predicting perioperative cardiac events. Am J Cardiol 2000; 85:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/61\">",
"      Labib SB, Goldstein M, Kinnunen PM, Schick EC. Cardiac events in patients with negative maximal versus negative submaximal dobutamine echocardiograms undergoing noncardiac surgery: importance of resting wall motion abnormalities. J Am Coll Cardiol 2004; 44:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/62\">",
"      Boersma E, Poldermans D, Bax JJ, et al. Predictors of cardiac events after major vascular surgery: Role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. JAMA 2001; 285:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/63\">",
"      Das MK, Pellikka PA, Mahoney DW, et al. Assessment of cardiac risk before nonvascular surgery: dobutamine stress echocardiography in 530 patients. J Am Coll Cardiol 2000; 35:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/64\">",
"      Rohde LE, Polanczyk CA, Goldman L, et al. Usefulness of transthoracic echocardiography as a tool for risk stratification of patients undergoing major noncardiac surgery. Am J Cardiol 2001; 87:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/65\">",
"      Halm EA, Browner WS, Tubau JF, et al. Echocardiography for assessing cardiac risk in patients having noncardiac surgery. Study of Perioperative Ischemia Research Group. Ann Intern Med 1996; 125:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/66\">",
"      Raby KE, Goldman L, Creager MA, et al. Correlation between preoperative ischemia and major cardiac events after peripheral vascular surgery. N Engl J Med 1989; 321:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/67\">",
"      Raby KE, Barry J, Creager MA, et al. Detection and significance of intraoperative and postoperative myocardial ischemia in peripheral vascular surgery. JAMA 1992; 268:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/68\">",
"      Mangano DT, Browner WS, Hollenberg M, et al. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group. N Engl J Med 1990; 323:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/69\">",
"      Wesorick DH, Eagle KA. The preoperative cardiovascular evaluation of the intermediate-risk patient: new data, changing strategies. Am J Med 2005; 118:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/70\">",
"      Bartels C, Bechtel JF, Hossmann V, Horsch S. Cardiac risk stratification for high-risk vascular surgery. Circulation 1997; 95:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/71\">",
"      Froehlich JB, Karavite D, Russman PL, et al. American College of Cardiology/American Heart Association preoperative assessment guidelines reduce resource utilization before aortic surgery. J Vasc Surg 2002; 36:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/60/36810/abstract/72\">",
"      Almanaseer Y, Mukherjee D, Kline-Rogers EM, et al. Implementation of the ACC/AHA guidelines for preoperative cardiac risk assessment in a general medicine preoperative clinic: improving efficiency and preserving outcomes. Cardiology 2005; 103:24.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6616 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-D438A33F91-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_60_36810=[""].join("\n");
var outline_f35_60_36810=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Functional capacity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Resting electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Guideline recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL PREDICTORS OF PERIOPERATIVE RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Major predictors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Recent MI or severe angina",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Recent PCI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H166915859\">",
"      - Decompensated heart failure or significant valvular heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Significant arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other clinical predictors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Obese patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Minor predictors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SURGERY-SPECIFIC RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H114518093\">",
"      Invasive dental procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      RISK MODELS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Goldman risk index",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Revised cardiac risk index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3260416\">",
"      NSQIP database risk model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Detsky modified risk index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Eagle criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Fleisher-Eagle criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      NONINVASIVE CARDIAC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Algorithmic approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - ACC/AHA guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - ACP guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Fleisher-Eagle algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Choice of stress test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Exercise stress testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Pharmacologic stress testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Dipyridamole rMPI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Dobutamine echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Resting echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H538698649\">",
"      Troponin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Ischemia monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Initial risk assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Refinement of initial risk estimate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Stress testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Resting echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Preoperative revascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Urgency of surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      - Emergent surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      - Urgent surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/6616\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/6616|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/11/9406\" title=\"figure 1\">",
"      Cardiac risk increases with the number of risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/45/33501\" title=\"figure 2\">",
"      Dobutamine echo surgical risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/49/16159\" title=\"figure 3\">",
"      Dobutamine echo outcome surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/6616|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/56/27532\" title=\"table 1\">",
"      ACC AHA prediction periop risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/2/7212\" title=\"table 2\">",
"      ACC AHA CV risk noncard surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/6/19564\" title=\"table 3\">",
"      ACC AHA preoperative ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 4\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/4/43083\" title=\"table 5\">",
"      Revised cardiac risk index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/62/30700\" title=\"table 6\">",
"      Goldman cardiac risk index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/33/8733\" title=\"table 7\">",
"      American Society of Anesthesiologists physical status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/24/40332\" title=\"table 8\">",
"      Detsky cardiac risk index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/24/7564\" title=\"table 9\">",
"      ACC AHA preop stress test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/2/34859\" title=\"table 10\">",
"      ACC AHA preop LV function",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35192?source=related_link\">",
"      Basic properties of myocardial perfusion agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7320?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16873?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33398?source=related_link\">",
"      Functional exercise testing: Ventilatory gas analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=related_link\">",
"      Management of cardiac risk for noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/14/13544?source=related_link\">",
"      Noncardiac surgery in patients with aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/35/3641?source=related_link\">",
"      Obesity, weight reduction, and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35945?source=related_link\">",
"      Performance of exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18440?source=related_link\">",
"      Perioperative heart failure in noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29975?source=related_link\">",
"      Perioperative myocardial infarction after noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/43/2746?source=related_link\">",
"      Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/52/35658?source=related_link\">",
"      Risk stratification for cardiac events after acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=related_link\">",
"      Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43081?source=related_link\">",
"      Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_60_36811="Total fetal loss rate2";
var content_f35_60_36811=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Total fetal loss rate: TC CVS compared with amniocentesis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Study, year",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Total loss rate, percent",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Difference percentage",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Relative risk, 95 percent CI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        TC CVS",
"       </td>",
"       <td class=\"subtitle2\">",
"        Amniocentesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Borrell (1999)",
"       </td>",
"       <td>",
"        19.5 (83/425)",
"       </td>",
"       <td>",
"        14.0 (57/407)",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"       <td>",
"        1.4 (1.03-1.9)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lippman (1992)",
"       </td>",
"       <td>",
"        17.2 (232/1348)",
"       </td>",
"       <td>",
"        15.7 (208/1324)",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        1.1 (0.9-1.3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smidt-Jensen",
"       </td>",
"       <td>",
"        11.9 (127/1068)",
"       </td>",
"       <td>",
"        7.0 (81/1158)",
"       </td>",
"       <td>",
"        4.9",
"       </td>",
"       <td>",
"        1.7 (1.3-2.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MRC (1991)",
"       </td>",
"       <td>",
"        7.3 (29/399)",
"       </td>",
"       <td>",
"        4.0 (16/398)",
"       </td>",
"       <td>",
"        3.2",
"       </td>",
"       <td>",
"        1.8 (1.0-3.3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overall",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        1.3 (1.2-1.5)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MRC: Medical Research Council.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_60_36811=[""].join("\n");
var outline_f35_60_36811=null;
var title_f35_60_36812="DFSP outcomes RT conserv surg";
var content_f35_60_36812=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dermatofibrosarcoma protuberans: Outcomes after radiotherapy alone or combined with conservative surgery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Series",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Follow-up",
"       </td>",
"       <td class=\"subtitle1\">",
"        Previous treatment, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Surgical margins",
"       </td>",
"       <td class=\"subtitle1\">",
"        Local control, percent (interval)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Suit H; 1996",
"       </td>",
"       <td rowspan=\"2\">",
"        18",
"       </td>",
"       <td rowspan=\"2\">",
"        &ndash;",
"       </td>",
"       <td rowspan=\"2\">",
"        39",
"       </td>",
"       <td>",
"        Positive/close (15)",
"       </td>",
"       <td>",
"        84 (10 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intralesional (3)",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Haas R; 1997",
"       </td>",
"       <td rowspan=\"2\">",
"        17",
"       </td>",
"       <td rowspan=\"2\">",
"        1 to 22 years",
"       </td>",
"       <td rowspan=\"2\">",
"        41",
"       </td>",
"       <td>",
"        Narrow (7)",
"       </td>",
"       <td rowspan=\"2\">",
"        82",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positive (5)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Ballo MT; 1998",
"       </td>",
"       <td rowspan=\"2\">",
"        19",
"       </td>",
"       <td rowspan=\"2\">",
"        Median, 6-years",
"       </td>",
"       <td rowspan=\"2\">",
"        &ndash;",
"       </td>",
"       <td>",
"        Negative (10), positive (6)",
"       </td>",
"       <td rowspan=\"2\">",
"        95 (10 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intralesional (1)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Sun LM; 2000",
"       </td>",
"       <td rowspan=\"2\">",
"        10",
"       </td>",
"       <td rowspan=\"2\">",
"        &ndash;",
"       </td>",
"       <td rowspan=\"2\">",
"        &ndash;",
"       </td>",
"       <td>",
"        Positive or close (6)",
"       </td>",
"       <td rowspan=\"2\">",
"        80 (7 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Negative (4)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Stojadinovic A; 2000",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        &ndash;",
"       </td>",
"       <td>",
"        &ndash;",
"       </td>",
"       <td>",
"        Positive (4)",
"       </td>",
"       <td>",
"        75*",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        DuBay D; 2004",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &ndash;",
"       </td>",
"       <td>",
"        &ndash;",
"       </td>",
"       <td>",
"        Positive (2)",
"       </td>",
"       <td>",
"        100*",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Dagan R; 2005",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        21 to 185 months",
"       </td>",
"       <td>",
"        &ndash;",
"       </td>",
"       <td>",
"        Marginal/intralesional (10)",
"       </td>",
"       <td>",
"        90*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Intralesional: gross disease.",
"     <br/>",
"     * Crude percentage, interval variable. Nine patients with DFSP were locally controlled; one patient with DFSP-FS recurred locally.",
"    </div>",
"    <div class=\"reference\">",
"     Dagan R. Am J Clin Oncol 2005; 28:537.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_60_36812=[""].join("\n");
var outline_f35_60_36812=null;
var title_f35_60_36813="Contents: Acne and rosacea";
var content_f35_60_36813=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Acne and rosacea",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Acne and rosacea",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acne",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/35/44599\">",
"           Hormonal therapy for women with acne vulgaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/54/33639\">",
"           Light-based, adjunctive, and other therapies for acne vulgaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/42/22184\">",
"           Oral isotretinoin therapy for acne vulgaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/20/6474\">",
"           Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/9/44183\">",
"           Postadolescent acne in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/28/39370\">",
"           Treatment of acne vulgaris",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Perioral dermatitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/55/9081\">",
"           Perioral (periorificial) dermatitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rosacea",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/24/29066\">",
"           Management of rosacea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/60/34761\">",
"           Ocular rosacea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/46/36584\">",
"           Rosacea: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-75C51550A6-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f35_60_36813=[""].join("\n");
var outline_f35_60_36813=null;
var title_f35_60_36814="Component separation technique with mesh";
var content_f35_60_36814=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Component separation technique with mesh",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 184px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows the repair of the abdominal wall defect using the component separation technique and mesh.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_60_36814=[""].join("\n");
var outline_f35_60_36814=null;
var title_f35_60_36815="Back stretch";
var content_f35_60_36815=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flexibility exercise: Back",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This exercise is for your back muscles. If you've had hip or back surgery, talk with your doctor before trying this stretch.",
"    <ol>",
"     <li>",
"      Sit securely toward the front of a sturdy, armless chair with your feet flat on the floor, shoulder-width apart.",
"     </li>",
"     <li>",
"      Slowly bend forward from your hips. Keep your back and neck straight.",
"     </li>",
"     <li>",
"      Slightly relax your neck and lower your chin. Slowly bend farther forward and slide your hands down your legs toward your shins. Stop when you feel a stretch or slight discomfort.",
"     </li>",
"     <li>",
"      Hold for 10 to 30 seconds.",
"     </li>",
"     <li>",
"      Straighten up slowly all the way to the starting position.",
"     </li>",
"     <li>",
"      Repeat at least three to five times.",
"     </li>",
"    </ol>",
"    As you progress, bend as far forward as you can and eventually touch your heels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_60_36815=[""].join("\n");
var outline_f35_60_36815=null;
